



November 13, 2025

To,
Corporate Relationship Department
BSE Limited
P. J. Towers, 1st Floor,
Dalal Street, Mumbai-400001

Scrip Code: 526169

Dear Sir/ Madam,

Sub.: Newspaper publication of Un-Audited Financial Results for the quarter and half year ended September 30, 2025

Pursuant to Regulation 47 of Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of newspaper advertisement with respect to the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2025, published in the Newspapers on November 13, 2025.

Kindly take the above on record and oblige.

Thanking you,

Yours truly,

For Multibase India Limited

Parmy Kamani
Company Secretary & Compliance Officer
M. No.: A27788

Multibase India Limited



PHARMAIDS PHARMACEUTICALS LIMITED

CIN - L5250KA1989PLC173079

Registered Office: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore-560013, INDIA. Tel: 080-49784319
E-mail Id: compliance@pharmalids.com | Website: www.pharmalids.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER, 2025.

The Board of Pharmalids Pharmaceuticals Limited (the Company), at its Meeting held on Tuesday, November 11, 2025, approved the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025.



The said financial results along with Limited Review Reports are available on Stock Exchange website (www.bseindia.com) and on the Company's website (<https://www.pharmalids.com/financialresults.html>). The same can be accessed by scanning the Quick Response Code provided.

By order of the Board of Directors
For Pharmalids Pharmaceuticals Limited

Sd/-

Venu Madhava Kaparthu

Whole-Time Director

(DIN:00021699)

Date: 11-11-2025, Place: Bengaluru

Note: The above information is in accordance with Regulations 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

KOHIMA-MARIANI TRANSMISSION LIMITED

(An Aprava Energy Company)

Registered Office: Unit No. T-15 A, Sakon Ras Vilas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel: +91 11 4302 5608
Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099.
Tel: +91 22 6756 8888, Fax: +91 22 6756 8811 / 8833
Website: www.aprava.com | CIN: U40102DL2016PLC03233



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025

Kohima-Mariani Transmission Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/kohima-mariani-transmission-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debit-ether/qrcode/9759311/debit-corp-announcements>).



Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Kohima-Mariani Transmission Limited

Sd/-

Deepa Sebastian

Director

(DIN: 09443732)

Date: 12 November 2025

Place: Mumbai, India



MULTIBASE INDIA LIMITED

Regd. Off & Factory Site: 74/5-B, Danner Industrial Estate, Kadipalya Village, Nam Damani - 206 210 (Union Territory)

• Phone: (0260) 9614400 • Fax: (0260) 2221578 • Website: www.multibaseindia.com

• E-mail: compliance.officer@multibaseindia.com • CIN: L01122DD1991PLC002959

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Sr. No.	Particular	Quarter Ended						Half Year Ended		Year Ended
		Quarter ended September 30, 2025	Quarter ended June 30, 2025	Quarter ended September 30, 2024	Quarter ended June 30, 2024	Quarter ended September 30, 2023	Quarter ended June 30, 2023	Half year ended September 30, 2025	Half year ended June 30, 2025	Year ended March 31, 2025
1	Total Income from Operations	1,930.16	1,762.47	2,043.63	3,692.63	4,159.89	7,880.05			
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	386.39	307.83	575.70	694.22	1101.60	1969.39			
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	386.39	307.83	575.70	694.22	1101.60	1969.39			
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	286.29	229.65	428.80	515.94	821.07	1465.49			
5	Total Comprehensive Income (Comprising Profit / (Loss) after tax and Other Comprehensive Income after tax)	286.29	229.65	428.80	515.94	821.07	1465.49			
6	Equity Share Capital (Face value of share: ₹10/-)	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00			
7	Other Equity	7,104.92	0.00	12,637.19	7,104.92	12,637.19	6,588.96			
8	Earnings per equity share in ₹									
(i) Basic		2.37	1.82	3.40	4.08	6.51	11.81			
(ii) Diluted		2.37	1.82	3.40	4.08	6.51	11.81			

Notes: The above is an extract of the detailed format of unaudited financial results for the quarter and half year ended September 30, 2025 filed with BSE Ltd. under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the said quarter is available on the website of BSE Ltd. (www.bseindia.com) and company's website at www.multibaseindia.com. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025.

REDEMPTION OF TRANSFER DEEDS

Please note that a special window has been opened for the re-issuance of transfer deeds. This window is available for transfer deeds lodged before the deadline of April 01, 2019, which were rejected, returned, or unattended due to deficiencies in the documents, processes, or other reasons. This special window will remain open for six months, from July 07, 2025, until January 06, 2026.

SAKSHAM NIVESHAK

Multibase India Limited is proud to support the IEPFA Saksham Niveshak 100-Day Campaign an initiative designed to help investors reclaim forgotten shares and undivided dividends. If you or someone you know has lost track of physical share certificates or dividends, now is the time to act.



For Multibase India Limited

Sd/-

Pankaj Kumar Malani

(Managing Director)

(DIN 10643892)

Place: Mumbai
Date: November 12, 2025

Scan me!

JHAJJAR POWER LIMITED

(An Aprava Energy Company)

Registered Office: Unit No. T-15 B, Sakon Ras Vilas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel: +91 11 4302 5608
Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099.
Tel: +91 22 6756 8888, Fax: +91 22 6756 8811 / 8833
Website: www.aprava.com | CIN: U40104DL2008PLC374107



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025

Jhajjar Power Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/jhajjar-power-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debit-ether/qrcode/9520111/debit-corp-announcements>).



Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Jhajjar Power Limited

Sd/-

Bhaskar Bhattacharjee

Whole-time Director

(DIN: 06309161)

Date: 12 November 2025

Place: Mumbai, India

Eris

ERIS LIFESCIENCES LIMITED

Regd. Office: Shivarth Ambit, Plot No 14/22, Ramdas Road Off SBR, Near Swast Bungalows, Bodakdev, Ahmedabad, Gujarat-380054. Email: compliance.officer@erislifesciences.com Website: www.eris.co.in
Tel: +91 79 6966 1000, Fax: +91 79 6966 1155, CIN: L24232GJ2007PLC049867

EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Particulars	[₹ in crores except per share data]					
	For Quarter Ended (Unaudited) September 30, 2025	For Quarter Ended (Unaudited) June 30, 2025	For Quarter Ended (Unaudited) September 30, 2024	For Half Year Ended (Unaudited) September 30, 2025	For Half Year Ended (Unaudited) September 30, 2024	For Year Ended (Audited) March 31, 2025
Revenue from Operations	792.41	773.00	741.17	1,565.41	1,460.89	2,893.64
Net Profit for the period before tax and exceptional items	172.67	161.10	129.21	333.77	244.73	468.87
Net Profit for the period before tax and after exceptional items	172.67	161.10	129.21	333.77	244.73	468.87
Net Profit for the period after tax	134.47	125.10	96.41	258.57	185.96	374.67
Total Comprehensive Income for the period after tax	133.90	124.53	96.25	258.43	185.01	371.38
Equity Share Capital (Face Value of ₹1 each)	13.62	13.62	13.61	13.62	13.61	13.62
Other Equity	3,077.54	2,960.97	2,757.87	3,077.54	2,757.87	2,840.74
Net Worth	3,053.48	3,099.10	3,177.34	3,053.48	3,177.34	3,271.76
Paid-up Debt Capital/Outstanding Debt	2,334.37	2,448.61	2,695.24	2,334.37	2,695.24	2,421.66
Outstanding Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
Debt Equity Ratio	0.68	0.74	0.86	0.68	0.86	0.76
Earnings Per Share (of ₹1 each) (not annualised) :						
Basic	8.82	8.66	6.73	17.49	12.84	25.85
Diluted	8.81	8.64	6.72	17.46	12.82	25.81
Capital Redemption Reserve	0.17	0.17	0.17	0.17	0.17	0.17
Debit Redemption Reserve	-	-	-	-	-	-
Debt Service Coverage Ratio	2.65	2.60	2.15	2.63	2.18	2.24
Interest Service Coverage Ratio	4.48	4.29	3.17	4.39	3.04	3.11

Notes: 1. Summary of standalone financial results of Eris Lifesciences Limited:

Particulars	[₹ in crores except per share data]					
	For Quarter Ended (Unaudited) September 30, 2025	For Quarter Ended (Unaudited) June 30, 2025	For Quarter Ended (Unaudited) September 30, 2024	For Half Year Ended (Unaudited) September 30, 2025	For Half Year Ended (Unaudited) September 30, 2024	For Year Ended (Audited) March 31, 2025
Revenue from Operations	650.50	578.64	436.56	1,229.14	893.25	1,697.75
Profit before tax	234.67	156.26	46.02	390.93	72.84	120.05
Profit after tax	149.57	99.99	28.10	249.56	45.14	77.39
Total Comprehensive Income (after tax)	149.07	99.49	27.99	248.56	44.31	74.55

2. The above is an extract of the detailed format of quarterly financial results filed with the stock exchange under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the stock exchanges websites (www.nseindia.com and www.bseindia.com) and on the company's website www.eris.co.in.
3. For the other line items referred in Regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to the Stock Exchange(s) (www.nseindia.com) and can be accessed on the company's website www.eris.co.in.
4. The above results were reviewed by the Audit Committee and approved by the Board at their meeting held on November 12, 2025.



Place: Ahmedabad
Date: November 12, 2025

For Eris Lifesciences Limited

Sd/-

Chairman and Managing Director

(DIN: 0072121)

THE BUSINESS DAILY
FOR DAILY BUSINESS

LAXMI DENTAL LIMITED (Formerly known as Laxmi Dental Export Private Limited) (CIN: L51507MH2004PLC147394) Registered Office: OFFICE NO. 103, AKRUTI ARCADE, J.P. ROAD, OPPOSITE A.H. WADIA HIGH SCHOOL, ANDHERI WEST, MUMBAI, MAHARASHTRA, INDIA, 400058 Tel: +91 - 22 - 6143 7991 E-mail: co.se@laxmidentallimited.com Website: www.laxmidentallimited.com											
EXTRACTS OF THE UNAUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025											
Particulars	Consolidated						Standalone				
	Quarter ended September 30, 2025 (Unaudited)	Quarter ended June 30, 2025 (Unaudited)	Quarter ended September 30, 2024 (Unaudited)	Quarter ended June 30, 2024 (Unaudited)	Quarter ended September 30, 2023 (Unaudited)	Quarter ended June 30, 2023 (Unaudited)	Quarter ended September 30, 2025 (Unaudited)	Quarter ended June 30, 2025 (Unaudited)	Quarter ended September 30, 2024 (Unaudited)	Quarter ended June 30, 2024 (Unaudited)	Quarter ended September 30, 2023 (Unaudited)
1 Total Income from operations	722.65	655.97	571.19	1,378.62	1,167.80	2,391.08	542.57	501.12	419.83	1,043.70	852.17
2 Net Profit for the period (before Tax, Exceptional and/or Extraordinary Items)	94.22	95.95	48.77	190.17	144.86	248.02	72.75	89.96	25.39	162.71	85.64
3 Net Profit for the period before tax (after Exceptional and/or Extraordinary Items)	94.22	95.95	48.77	190.17	211.03	318.29	72.75	89.96	25.39	162.71	151.81
4 Net Profit for the period after tax (after Exceptional and/or Extraordinary Items)	85.32	83.30	58.95	168.62	227.39	318.34	65.70	78.59	37.96	144.29	183.84
5 Total Comprehensive Income (after tax)	87.35	82.46	59.83	169.81	227.17	313.00	64.33	77.22	36.38	141.55	182.26
6 Equity Share Capital (Face Value Rs 2 each)	109.92	109.92	55.63	109.92	55.63	109.92	109.92	109.92	55.63	109.92	55.63
7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	1,975.45	-	-	-	-	-
8 Earning Per Share of Rs 2 each (before and after extraordinary items)											
Basic:	1.59	1.53	1.14	3.12	4.39	6.07	1.20	1.43	0.73	2.63	3.55
Diluted:	1.58	1.52	1.14	3.10	4.39	6.05	1.19	1.42	0.73	2.61	3.55

Notes: a. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 11, 2025.
b. The above is an extract of the detailed format of the Consolidated and Standalone Financial Results for the quarter and half year ended September 30, 2025 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the websites of the Company, National Stock Exchange of India Limited and BSE Limited at www.laxmidentallimited.com, www.nseindia.com and www.bseindia.com, respectively.

Place: Mumbai
Date: November 11, 2025



For and on behalf of the Board of Directors

Sd/-

Suresh Kamlesh Merchant

CEO & Managing Director

(DIN: 00679893)



PHARMAIDS PHARMACEUTICALS LIMITED

CIN - L5250KA1989PLC173079

Registered Office: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore-560013, INDIA. Tel: 080-49784319
E-mail Id: compliance@pharmalids.com | Website: www.pharmalids.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER, 2025.

The Board of Pharmalids Pharmaceuticals Limited (the Company), at its Meeting held on Tuesday, November 11, 2025, approved the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025.



The said financial results along with Limited Review Reports are available on Stock Exchange website (www.bseindia.com) and on the Company's website (<https://www.pharmalids.com/financialresults.html>). The same can be accessed by scanning the Quick Response Code provided.

By order of the Board of Directors
For Pharmalids Pharmaceuticals Limited

Sd/-
Venu Madhava Kaparthu

Whole-Time Director
(DIN:00021699)

Date: 11-11-2025, Place: Bengaluru

Note: The above information is in accordance with Regulations 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

KOHIMA-MARIANI TRANSMISSION LIMITED

(An Aprava Energy Company)

Registered Office: Unit No. T-15 A, Sakon Ras Vilas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel: +91 11 4302 5608
Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099.
Tel: +91 22 6758 8888, Fax: +91 22 6758 8811 / 8833
Website: www.aprava.com | CIN: U40102DL2016PLC403233



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025

Kohima-Mariani Transmission Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/kohima-mariani-transmission-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debit-ether/qrcode/9759311debit-corp-announcements>).



Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Kohima-Mariani Transmission Limited

Sd/-
Deepa Sebastian

Director
(DIN: 09443732)

Date: 12 November 2025
Place: Mumbai, India



MULTIBASE INDIA LIMITED

Regd. Off & Factory Site: 74/5-B, Danner Industrial Estate, Kadipalya Village, Nam Damani - 206 210 (Union Territory)
• Phone: (0260) 9614400 • Fax: (0260) 2221578 • Website: www.multibaseindia.com
• E-mail: compliance.officer@multibaseindia.com • CIN: L01122DD1991PLC002959

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Sr. No.	Particular	Quarter Ended						Half Year Ended		Year Ended	
		Quarter ended September 30, 2025	Quarter ended June 30, 2025	Quarter ended September 30, 2024	Quarter ended June 30, 2024	Quarter ended September 30, 2023	Quarter ended June 30, 2023	Half year ended September 30, 2025	Half year ended June 30, 2025	Year ended March 31, 2025	Year ended March 31, 2024
1	Total Income from Operations	1,930.16	1,762.47	2,043.63	3,692.63	4,159.89	7,680.05				
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	386.39	307.83	575.70	694.22	1101.60	1969.39				
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	386.39	307.83	575.70	694.22	1101.60	1969.39				
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	286.29	229.65	428.80	515.94	821.07	1465.49				
5	Total Comprehensive Income (Comprising Profit/ (Loss) after tax and Other Comprehensive Income after tax)	286.29	229.65	428.80	515.94	821.07	1465.49				
6	Equity Share Capital (Face value of share: ₹10/-)	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00				
7	Other Equity	7,104.92	0.00	12,637.19	7,104.92	12,637.19	6,588.96				
8	Earnings per equity share in ₹										
(i) Basic:		2.37	1.82	3.40	4.08	6.51	11.81				
(ii) Diluted:		2.37	1.82	3.40	4.08	6.51	11.81				

Notes: The above is an extract of the detailed format of unaudited financial results for the quarter and half year ended September 30, 2025 filed with BSE Ltd. under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the said quarter is available on the website of BSE Ltd. (www.bseindia.com) and company's website at www.multibaseindia.com. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025.

RELODGE/MENT OF TRANSFER DEEDS

Please note that a special window has been opened for the re-lodgement of transfer deeds. This window is available for transfer deeds lodged before the deadline of April 01, 2019, which were rejected, returned, or unattended due to deficiencies in the documents, processes, or other reasons. This special window will remain open for six months, from July 07, 2025, until January 06, 2026.

SAKSHAM NIVESHAK

Multibase India Limited is proud to support the IEPFA Saksham Niveshak 100-Day Campaign an initiative designed to help investors reclaim forgotten shares and undivided dividends. If you or someone you know has lost track of physical share certificates or dividends, now is the time to act.



For Multibase India Limited
Sd/-
Prabhakumar Malani

(Managing Director)
(DIN 10643892)

Place: Mumbai
Date: November 12, 2025

Scan me!

JHAJJAR POWER LIMITED

(An Aprava Energy Company)

Registered Office: Unit No. T-15 B, Sakon Ras Vilas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel: +91 11 4302 5608
Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099.
Tel: +91 22 6758 8888, Fax: +91 22 6758 8811 / 8833
Website: www.aprava.com | CIN: U40104DL2008PLC374107



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025

Jhajjar Power Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/jhajjar-power-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debit-ether/qrcode/9520311debit-corp-announcements>).



Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Jhajjar Power Limited

Sd/-
Bhaskar Bhattacharjee

Whole-time Director
(DIN: 06309161)

Date: 12 November 2025
Place: Mumbai, India

Eris

ERIS LIFESCIENCES LIMITED

Regd. Office: Shivarth Ambit, Plot No 14/22, Ramdas Road Off SBR, Near Swast Bungalows, Bodakdev, Ahmedabad, Gujarat-380054. Email: compliance.officer@erislifesciences.com Website: www.eris.co.in
Tel: +91 79 6966 1000, Fax: +91 79 6966 1155, CIN: L24232GJ2007PLC049867

EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Particulars	[₹ in crores except per share data]					
	For Quarter Ended (Unaudited) September 30, 2025	For Quarter Ended (Unaudited) June 30, 2025	For Quarter Ended (Unaudited) September 30, 2024	For Half Year Ended (Unaudited) September 30, 2025	For Half Year Ended (Unaudited) September 30, 2024	For Year Ended (Audited) March 31, 2025
Revenue from Operations	792.41	773.00	741.17	1,565.41	1,460.89	2,893.64
Net Profit for the period before tax and exceptional items	172.67	161.10	129.21	333.77	244.73	468.87
Net Profit for the period before tax and after exceptional items	172.67	161.10	129.21	333.77	244.73	468.87
Net Profit for the period after tax	134.47	125.10	96.41	259.57	185.96	374.67
Total Comprehensive Income for the period after tax	133.90	124.53	96.25	258.43	185.01	371.38
Equity Share Capital (Face Value of ₹1 each)	13.62	13.62	13.61	13.62	13.61	13.62
Other Equity	3,077.54	2,960.97	2,757.87	3,077.54	2,757.87	2,840.74
Net Worth	3,053.48	3,099.10	3,177.34	3,053.48	3,177.34	3,271.76
Paid-up Debt Capital/Outstanding Debt	2,334.37	2,448.61	2,695.24	2,334.37	2,695.24	2,421.66
Outstanding Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
Debt Equity Ratio	0.68	0.74	0.86	0.68	0.86	0.76
Earnings Per Share (of ₹1 each) (not annualised):						
Basic	8.82	8.66	6.73	17.49	12.84	25.85
Diluted	8.81	8.64	6.72	17.46	12.82	25.81
Capital Redemption Reserve	0.17	0.17	0.17	0.17	0.17	0.17
Debit Redemption Reserve	-	-	-	-	-	-
Debt Service Coverage Ratio	2.65	2.60	2.15	2.63	2.18	2.24
Interest Service Coverage Ratio	4.48	4.29	3.17	4.39	3.04	3.11

Notes: 1. Summary of standalone financial results of Eris Lifesciences Limited:

Particulars	[₹ in crores except per share data]					
	For Quarter Ended (Unaudited) September 30, 2025	For Quarter Ended (Unaudited) June 30, 2025	For Quarter Ended (Unaudited) September 30, 2024	For Half Year Ended (Unaudited) September 30, 2025	For Half Year Ended (Unaudited) September 30, 2024	For Year Ended (Audited) March 31, 2025
Revenue from Operations	650.50	578.64	436.56	1,229.14	893.25	1,697.75
Profit before tax	234.67	156.26	46.02	390.93	72.84	120.05
Profit after tax	149.57	99.99	28.10	249.56	45.14	77.39
Total Comprehensive Income (after tax)	149.07	99.49	27.99	248.56	44.31	74.55

2. The above is an extract of the detailed format of quarterly financial results filed with the stock exchange under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the stock exchanges websites (www.nseindia.com and www.bseindia.com) and on the company's website www.eris.co.in.

3. For the other line items referred in Regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to the Stock Exchange(s) (www.nseindia.com) and can be accessed on the company's website www.eris.co.in.

4. The above results were reviewed by the Audit Committee and approved by the Board at their meeting held on November 12, 2025.



Place: Ahmedabad
Date: November 12, 2025

For Eris Lifesciences Limited
Sd/-
Chairman and Managing Director

(Address: 807/23)



LAXMI DENTAL LIMITED

(Formerly known as Laxmi Dental Export Private Limited)

Registered Office: OFFICE NO. 103, AKRUTI ARCADE, J.P. ROAD, OPPOSITE A.H. WADIA HIGH SCHOOL, ANDHERI WEST, MUMBAI, MAHARASHTRA, INDIA, 400058
Tel: +91 22 6143 7991 E-mail: co.se@laxmidentallimited.com Website: www.laxmidentallimited.com
CIN: L51507MH2004PLC147394

EXTRACTS OF THE UNAUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

(Rs in Millions)

Particulars	Consolidated						Standalone					
	Quarter ended September 30, 2025 (Unaudited)	Quarter ended June 30, 2025 (Unaudited)	Quarter ended September 30, 2024 (Unaudited)	Quarter ended June 30, 2024 (Unaudited)	Quarter ended September 30, 2023 (Unaudited)	Quarter ended June 30, 2023 (Unaudited)	Quarter ended September 30, 2025 (Unaudited)	Quarter ended June 30, 2025 (Unaudited)	Quarter ended September 30, 2024 (Unaudited)	Quarter ended June 30, 2024 (Unaudited)	Quarter ended September 30, 2023 (Unaudited)	Quarter ended June 30, 2023 (Unaudited)
1 Total Income from operations	722.65	655.97	571.19	1,378.62	1,167.80	2,391.08	542.57	501.12	419.83	1,043.70	852.17	1,712.43
2 Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	94.22	95.95	48.77	190.17	144.86	248.02	72.75	89.96	25.39	162.71	85.64	173.27
3 Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	94.22	95.95	48.77	190.17	211.03	318.29	72.75	89.96	25.39	162.71	151.81	243.54
4 Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	85.32	83.30	58.95	168.62	227.39	318.34	65.70	78.59	37.96	144.29	183.84	257.75
5 Total Comprehensive Income (after tax)	87.35	82.46	59.83	169.81	227.17	313.00	64.33	77.22	36.38	141.55	182.26	252.27
6 Equity Share Capital (Face Value Rs 2 each)	109.92	109.92	55.63	109.92	55.63	109.92	109.92	109.92	55.63	109.92	55.63	109.92
7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	1,975.45	-	-	-	-	-	2,117.45
8 Earning Per Share of Rs 2 each (before and after extraordinary items)												
Basic:	1.59	1.53	1.14	3.12	4.39	6.07	1.20	1.43	0.73	2.63	3.55	4.92
Diluted:	1.58	1.52	1.14	3.10	4.39	6.05	1.19	1.42	0.73	2.61	3.55	4.91

Notes:

a. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 11, 2025.
b. The above is an extract of the detailed format of the Consolidated and Standalone Financial Results for the quarter and half year ended September 30, 2025 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the websites of the Company, National Stock Exchange of India Limited and BSE Limited at www.laxmidentallimited.com, www.nseindia.com and www.bseindia.com, respectively.

Place: Mumbai
Date: November 11, 2025



For and on behalf of the Board of Directors
Sd/-
Sanjeev Kamlesh Merchant

CEO & Managing Director
(DIN: 00679893)

PHARMAIDS PHARMACEUTICALS LIMITED
CIN - L52520KA1989PLC173079
Registered Office: Unit #201, Brigade Rubik, 20/14, HMT Factory Road, Peenya Plantation, Bangalore-560013, INDIA. Tel: 080-49784319
E-mail id: compliance@pharmaids.com | Website: www.pharmaids.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER, 2025.

The Board of Pharmaids Pharmaceuticals Limited ('the Company'), at its Meeting held on Tuesday, November 11, 2025, approved the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025.

The said financial results along with Limited Review Reports are available on Stock Exchange website (www.bseindia.com) and on the Company's website (<https://www.pharmaids.com/financialresults.html>). The same can be accessed by scanning the Quick Response Code provided.

By order of the Board of Directors
For Pharmaids Pharmaceuticals Limited
Sd/-
Venu Madhava Kaparthu
Whole-Time Director
(DIN:00021699)

Date: 11-11-2025, Place: Bengaluru

Note: The above information is in accordance with Regulations 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

KOHIMA-MARIANI TRANSMISSION LIMITED
(An Aprava Energy Company)
Registered Office: Unit No. T-15 A, Sakon Ras Vlas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel: +91 11 4302 5608
Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099.
Tel: +91 22 6758 8888, Fax: +91 22 6758 8811 / 8833
Website: www.aprava.com | CIN: U40102DL2016PLC403233

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025

Kohima-Mariani Transmission Limited ('the Company') hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ('Results') along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/kohima-mariani-transmission-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debt-often/iscpcode/952011/debt-corp-announcements>).

For and on behalf of Board of Directors of Kohima-Mariani Transmission Limited
Sd/-
Deepa Sebastian
Director
(DIN: 09443732)
Date: 12 November 2025
Place: Mumbai, India

MULTIBASE INDIA LIMITED
Regd. Off & Factory Site: 74/5-6, Damod Industries Estate, Kodagya Village, Nan Daman - 396 210 (Union Territory)
• Phone: (0269) 6614400 • Fax: (0269) 2221576 • Website: www.multibaseindia.com
• E-mail: compliance.officer@multibaseindia.com • CIN: L01122DO1991PLC002959

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Sr. No.	Particular	Quarter ended						Half-year ended		Year ended
		September 30, 2025	June 30, 2025	September 30, 2024	June 30, 2024	September 30, 2024	June 30, 2024	September 30, 2024	March 31, 2025	
1	Total Income from Operations	1,930.16	1,762.47	2,043.63	3,692.63	4,159.89	7,880.65			
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	366.39	307.83	575.70	694.22	1101.60	1969.39			
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	366.39	307.83	575.70	694.22	1101.60	1969.39			
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	286.29	229.65	428.80	515.94	821.07	1465.49			
5	Total Comprehensive Income (Comprising Profit / (Loss) after tax and Other Comprehensive Income after tax)	286.29	229.65	428.80	515.94	821.07	1465.49			
6	Equity Share Capital (Face value of share: ₹10/-)	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00			
7	Other Equity	7,104.92	0.00	12,637.19	7,104.92	12,637.19	6,588.96			
8	Earnings per equity share in ₹									
(i) Basic:		2.27	1.82	3.40	4.88	6.51	11.81			
(ii) Diluted:		2.27	1.82	3.40	4.88	6.51	11.81			

Note: The above is an extract of the detailed format of unaudited financial results for the quarter and nine months ended September 30, 2025 filed with BSE Ltd. under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the said quarter is available on the website of BSE Ltd. at www.bseindia.com and company's website at www.multibaseindia.com. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025.

RELINQUISHMENT OF TRANSFER DEEDS
Please note that a special window has been opened for the re-judgment of transfer deeds. This window is available for transfer deeds lodged before the deadline of April 01, 2019, which were rejected, returned, or unattended due to deficiencies in the documents, processes, or other reasons. This special window will remain open for six months, from July 07, 2025, until January 06, 2026.

SAKSHAM NIVESHAK
Multibase India Limited is proud to support the IEPFA Saksham Niveshak 100-Day Campaign an initiative designed to help investors reclaim forgotten shares and unclaimed dividends. If you or someone you know has lost track of physical share certificates or dividends, now is the time to act.

For Multibase India Limited
Sd/-
Pankaj Kumar Holani
(Managing Director)
(DIN 10843892)
Place: Mumbai
Date: November 12, 2025

JHAJJAR POWER LIMITED
(An Aprava Energy Company)
Registered Office: Unit No. T-15 B, Sakon Ras Vlas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel: +91 11 4302 5608
Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099.
Tel: +91 22 6758 8888, Fax: +91 22 6758 8811 / 8833
Website: www.aprava.com | CIN: U40104DL2008PLC374107

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025

Jhajjar Power Limited ('the Company') hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ('Results') along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (https://www.aprava.com/investor-and-compliance/investor-and-compliance_id) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debt-often/iscpcode/952011/debt-corp-announcements>).

For and on behalf of Board of Directors of Jhajjar Power Limited
Sd/-
Bhaskar Bhattacharjee
Whole-time Director
(DIN: 08309161)
Date: 12 November 2025
Place: Mumbai, India

Eris
ERIS LIFESCIENCES LIMITED
Regd. Office: Shivarth Ambit, Plot No 142/2, Ramdas Road Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat-380054. Email: compliance.officer@erislifesciences.com Website: www.eris.co.in,
Tel: +91 79 6966 1000, Fax: +91 79 6966 1155, CIN: L24232GJ2007PLC048867

EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

(₹ in crores except per share data)

Particulars	For Quarter ended (Unaudited) September 30, 2025	For Quarter ended (Unaudited) June 30, 2025	For Quarter ended (Unaudited) September 30, 2024	For Half Year ended (Unaudited) September 30, 2025	For Half Year ended (Unaudited) September 30, 2024	For Year ended (Audited) March 31, 2025
Revenue from Operations	792.41	773.00	741.17	1,565.41	1,460.89	2,893.64
Net Profit for the period before tax and exceptional items	172.67	161.10	129.21	333.77	244.73	488.87
Net Profit for the period before tax	172.67	161.10	129.21	333.77	244.73	488.87
Net Profit for the period after tax	134.47	125.10	96.41	259.57	185.96	374.67
Total Comprehensive Income for the period after tax	133.90	124.53	96.25	258.43	185.01	371.38
Equity Share Capital (Face Value of ₹1 each)	13.62	13.62	13.61	13.62	13.61	13.62
Other Equity	3,077.54	2,960.97	2,757.87	3,077.54	2,757.87	2,840.74
Net Worth	3,053.98	3,399.10	3,177.34	3,503.48	3,177.34	3,271.76
Paid-up Debt Capital/Outstanding Debt	2,334.37	2,448.61	2,695.24	2,334.37	2,695.24	2,421.66
Outstanding Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
Debt Equity Ratio	0.68	0.74	0.86	0.68	0.86	0.76
Earnings Per Share (of ₹1 each) (not annualised):						
Basic:	8.82	8.06	6.73	17.49	12.84	25.85
Diluted:	8.61	6.64	6.72	17.46	12.82	25.81
Capital Redemption Reserve	0.17	0.17	0.17	0.17	0.17	0.17
Debt Redemption Reserve	-	-	-	-	-	-
Debt Service Coverage Ratio	2.65	2.60	2.15	2.63	2.18	2.24
Interest Service Coverage Ratio	4.48	4.29	3.17	4.39	3.04	3.11

Notes:

- Summary of standalone financial results of Eris Lifesciences Limited:

(₹ in crores except per share data)

Particulars	For Quarter ended (Unaudited) September 30, 2025	For Quarter ended (Unaudited) June 30, 2025	For Quarter ended (Unaudited) September 30, 2024	For Half Year ended (Unaudited) September 30, 2025	For Half Year ended (Unaudited) September 30, 2024	For Year ended (Audited) March 31, 2025
Revenue from Operations	650.50	578.64	436.56	1,229.14	893.25	1,697.75
Profit before tax	234.67	156.26	46.02	390.93	72.84	120.05
Profit after tax	149.57	99.99	28.10	249.56	45.14	77.39
Total Comprehensive Income (after tax)	149.07	99.49	27.99	248.56	44.31	74.55

- The above is an extract of the detailed format of quarterly financial results filed with the stock exchange under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the stock exchanges website (www.bseindia.com and www.nseindia.com) and on the company's website www.eris.co.in.
- For the other line items referred in Regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to the Stock Exchange(s) (www.bseindia.com and www.nseindia.com) and can be accessed on the company's website www.eris.co.in.
- The above results were reviewed by the Audit Committee and approved by the Board at their meeting held on November 12, 2025.

Place: Ahmedabad
Date: November 12, 2025

For Eris Lifesciences Limited
Sd/-
Chairman and Managing Director

LAXMI DENTAL LIMITED
(Formerly known as Laxmi Dental Export Private Limited)
(CIN: L51507MH2004PLC147394)
Registered Office: OFFICE NO. 103, AKRUTI ARCADE, J.P. ROAD, OPPOSITE A.H. WADIA HIGH SCHOOL, ANDHERI WEST, MUMBAI, MAHARASHTRA, INDIA, 400058

EXTRACTS OF THE UNAUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025 (Rs in Millions)

Particulars	Consolidated						Standalone					
	Quarter ended			Half Year ended September 30, 2025			Quarter ended			Half Year ended September 30, 2025		
	September 30, 2025 (Unaudited)	June 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	March 31, 2025 (Audited)	September 30, 2025 (Unaudited)	June 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	March 31, 2025 (Audited)
1 Total Income from operations	722.65	655.97	571.19	1,378.62	1,167.80	2,391.08	542.57	501.12	419.83	1,043.70	852.17	1,712.43
2 Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	94.22	95.95	48.77	190.17	144.86	248.02	72.75	89.96	25.39	162.71	85.64	173.27
3 Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	94.22	95.95	48.77	190.17	211.03	318.29	72.75	89.96	25.39	162.71	151.81	243.54
4 Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	85.32	83.30	58.95	168.62	227.39	318.34	65.70	78.59	37.96	144.29	183.84	257.75
5 Total Comprehensive Income (after tax)	87.35	82.46	59.83	169.81	227.17	313.00	64.33	77.22	36.38	141.55	182.26	252.27
6 Equity Share Capital (Face Value ₹2 each)	109.92	109.92	55.63	109.92	55.63	109.92	109.92	109.92	55.63	109.92	55.63	109.92
7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	1,975.45	-	-	-	-	-	2,117.45
8 Earning Per Share of ₹2 each (before and after extraordinary items)												
Basic:	1.59	1.53	1.14	3.12	4.39	6.07	1.26	1.43	0.73	2.63	3.55	4.92
Diluted:	1.58	1.52	1.14	3.10	4.39	6.05	1.19	1.42	0.73	2.61	3.55	4.91

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 11, 2025.
- The above is an extract of the detailed format of the Consolidated and Standalone Financial Results for the quarter and half year ended September 30, 2025 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the websites of the Company, National Stock Exchange of India Limited and BSE Limited at www.laxmidentallimited.com, www.nseindia.com and www.bseindia.com, respectively.

Place: Mumbai
Date: November 11, 2025

For and on behalf of the Board of Directors
Sd/-
Samer Kaniash Merchant
CEO & Managing Director
(DIN: 06679893)

THE BUSINESS DAILY
FOR DAILY BUSINESS
#FINANCIAL EXPRESS

KOHIMA-MARIANI TRANSMISSION LIMITED

(An Aprava Energy Company)

Registered Office: Unit No. T-15 A, Saloon Ras Vilas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel: +91 11 4302 5608Corporate Office: 7th Floor, Fulum, Sahar Road, Andheri (East), Mumbai - 400 099.Tel: +91 22 6758 8888. Fax: +91 22 6758 8811 / 8833
Website: www.aprava.com | CIN: U40102DL2008PLC374107**STATEMENT OF UNAUDITED FINANCIAL RESULTS
FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025**

Kohima-Mariani Transmission Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/kohima-mariani-transmission-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price-detail-ohsrncpcode/975831/det-corp-announcements>).

Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Kohima-Mariani Transmission Limited

Sd/-
Deepa Sebastian
Director
DIN: 09443732Date: 12 November 2025
Place: Mumbai, India**JHAJJAR POWER LIMITED**

(An Aprava Energy Company)

Registered Office: Unit No. T-15 B, Saloon Ras Vilas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel: +91 11 4302 5608Corporate Office: 7th Floor, Fulum, Sahar Road, Andheri (East), Mumbai - 400 099.Tel: +91 22 6758 8888. Fax: +91 22 6758 8811 / 8833
Website: www.aprava.com | CIN: U40102DL2008PLC374107**STATEMENT OF UNAUDITED FINANCIAL RESULTS
FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025**

Jhajjar Power Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/jhajjar-power-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price-detail-ohsrncpcode/962011/det-corp-announcements>).

Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Jhajjar Power Limited

Sd/-
Bhaskar Bhattacharjee
Whole-time Director
DIN: 06309161Date: 12 November 2025
Place: Mumbai, India**PHARMAIDS PHARMACEUTICALS LIMITED**

CIN: L52520KA1989PLC13799

Registered Office: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore-560013, INDIA. Tel: 080-49784319
E-mail id: compliance@pharmajids.com | Website: www.pharmajids.com**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER, 2025.**

The Board of Pharmajids Pharmaceuticals Limited (the "Company"), at its Meeting held on Tuesday, November 11, 2025, approved the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025.

The said financial results along with Limited Review Reports are available on Stock Exchange website (www.bseindia.com) and on the Company's website (<https://www.pharmajids.com/financialresults.html>). The same can be accessed by scanning the Quick Response Code provided.By order of the Board of Directors
For Pharmajids Pharmaceuticals LimitedSd/-
Venu Madhava Kaparthi
Whole-time Director
(DIN:00021699)

Date: 11-11-2025, Place: Bengaluru

Note: The above information is in accordance with Regulations 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**MULTIBASE INDIA LIMITED**

Regd. Off & Factory Site: 74/5-B, Daman Industrial Estate, Kadya Village, Nani Daman - 395 210 (Union Territory)

Phone: (0260) 6614400 • Fax: (0260) 2221578 • Website: www.multibaseindia.comE-mail: compliance.officer@multibaseindia.com • CIN: L01122DD1981PLC002955**EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025**

Sr. No.	Particular	Quarter Ended						Half-year ended					
		September 30, 2025		June 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024		March 31, 2025	
		Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited
1	Total Income from Operations	1,930.16	1,762.47	2,043.63	3,692.63	4,159.89	7,680.65						
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	386.39	307.83	575.70	694.22	1101.60	1969.39						
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	386.39	307.83	575.70	694.22	1101.60	1969.39						
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	286.29	229.65	428.80	515.94	821.07	1465.49						
5	Total Comprehensive Income (Comprising Profit / (Loss) after tax and Other Comprehensive Income after tax)	286.29	229.65	428.80	515.94	821.07	1465.49						
6	Equity Share Capital (Face value of share: ₹10/-)	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00						
7	Other Equity	7,104.92	0.00	12,637.19	7,104.92	12,637.19	6,588.96						
8	Earnings per equity share in ₹												
(a) Basic:		2.27	1.82	3.40	4.09	6.51	11.61						
(b) Diluted:		2.27	1.82	3.40	4.09	6.51	11.61						

Note: The above is an extract of the detailed format of unaudited financial results for the quarter and nine months ended September 30, 2025 filed with BSE Ltd. under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the said quarter is available on the website of BSE Ltd. at www.bseindia.com and company's website at www.multibaseindia.com

The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025.

RE-DEPOSIT OF TRANSFER DEEDS
Please note that a special window has been opened for the re-deposit of transfer deeds. This window is available for transfer deeds lodged before the deadline of April 01, 2018, which were rejected, returned, or unattended due to deficiencies in the documents, processes, or other reasons. This special window will remain open for six months, from July 07, 2025, until January 06, 2026.**RECLAIMING UNCLAIMED DIVIDENDS**
Multibase India Limited is proud to support the IEPFA Scheme. Multibase India Limited has an initiative designed to help investors reclaim forgotten shares and unclaimed dividends. If you or someone you know has lost track of physical share certificates or dividends, now is the time to act.For Multibase India Limited
Sd/-
Pankaj Kumar Holani
(Managing Director)
(DIN 10843892)Place: Mumbai
Date: November 12, 2025

Scan me!

EAST COAST RAILWAY

e-Tender Notice No. STCR/SP-40, D-G-01115, Date: 07.11.2025

NAME OF WORK: SUPPLY, INSTALLATION, DESIGN & COMMISSIONING OF NEW ELECTRONIC INTERLOCKING (NOT STANDBY) WITH DISTRIBUTED ARCHITECTURE AT GATE JUNCTION (GJC), DUVVADA, GOPALAPATNAM (GPT) STATIONS AND SUPPLY, INSTALLATION, DESIGN & COMMISSIONING OF ALTERATION IN EXISTING ELECTRONIC INTERLOCKING (DISTRIBUTED) OF MS KRYGAN AT VADLAPUDI (VDP) STATION IN CONNECTION WITH 2nd & 4th LINE BETWEEN VADLAPUDI-GATE JUNCTION & DUVVADA-GOPALAPATNAM SECTIONS AND WORKING OF AUTOMATIC BLOCK WORKING BETWEEN VADLAPUDI-GATE JUNCTION & DUVVADA-GOPALAPATNAM SECTIONS INCLUDING UTILITY SHIFTING OF INFENDING LEVEL CROSSING GATE, CABLES, LOCATION BOXES, OTHER SIGNALING & TELECOMMUNICATION DEVICES IN WILKIN DIVISION OF EAST COAST RAILWAY.

e-Tender Notice No. STCR/SP-40, D-G-01115, Date: 07.11.2025

Completion Period of the Work: 18 (Eighteen) Months.

Tendering Commence Date & Time: At 1530 hrs. on 07.11.2025.

No manual offers sent by Post / Courier / Fax or in person shall be accepted against such e-tenders even if these are submitted on or before the date of closing of tender to the tendering authority.

All such manual offers shall be considered invalid and shall be rejected summarily without any consideration.

Complete information including e-tender documents of the above e-tender is available in website: www.epgp.gov.in

Note: 1. The prospective bidders are advised to visit the website 15 (Fifteen) days before the date of closing of tender to note any changes / corrigenda issued for this tender. The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

The bidders/tenders must have valid e-mail address and valid e-mail id.

LAXMI DENTAL LIMITED

(Formerly known as Laxmi Dental Export Private Limited)

CIN: L51907MH2004PLC47944

Registered Office: OFFICE NO. 101, AKRUTI ARCADE, 1st FLOOR, OPPOSITE A.P. WADIA HIGHER SCHOOL, ANDHERI WEST, MUMBAI, MAHARASHTRA, INDIA, 400058Tel: +91 - 22 - 6143 7991 E-mail: coo@laxmidental.com Website: www.laxmidental.com**EXTRACTS OF THE UNAUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025**

(Rs in Millions)

Particulars	Consolidated						Standalone					
	Quarter ended		Half Year ended		Year ended		Quarter ended		Half Year ended		Year ended	
	September 30, 2025 (Unaudited)	June 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	March 31, 2025 (Audited)	September 30, 2025 (Unaudited)	June 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	March 31, 2025 (Audited)
1	Total Income from operations	722.65	655.97	571.19	1,378.62	1,167.80	542.57	501.12	419.83	1,043.70	852.17	1,712.43
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary Items)	94.22	95.95	48.77	190.17	144.86	72.75	89.96	25.39	162.71	85.64	173.27
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary Items)	94.22	95.95	48.77	190.17	211.03	72.75	89.96	25.39	162.71	151.81	243.54
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary Items)	85.32	83.30	58.95	168.62	227.39	65.70	78.59	37.96	144.29	183.84	257.75
5	Total Comprehensive Income (after tax)	87.35	82.46	59.83	169.81	227.17	64.33	77.22	36.38	141.55	182.26	252.27
6	Equity Share Capital (Face Value Rs 2 each)	109.92	109.92	55.63	109.92	55.63	109.92	109.92	55.63	109.92	55.63	109.92
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	1,975.45	-	-	-	-	-	2,117.45
8	Earning Per Share of Rs 2 each (before and after extraordinary items)											
Basic:	1.59	1.53	1.14	3.12	4.39	6.07	1.20	1.43	0.73	2.63	3.55	4.92
Diluted:	1.58	1.52	1.14	3.10	4.39	6.05	1.18	1.42	0.73	2.61	3.55	4.91

Notes:

a. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 11, 2025.

b. The above is an extract of the detailed format of the Consolidated and Standalone Financial Results for the quarter and half year ended September 30, 2025 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the websites of the Company, National Stock Exchange of India Limited and BSE Limited at www.laxmidental.com, www.nseindia.com and www.bseindia.com, respectively.

Place: Mumbai

Date: November 11, 2025

For and on behalf of the Board of Directors

Sd/-
Samer Karmish Merchant
CEO & Managing Director
(DIN: 00678090)

epaper.financialexpress.com

KOHIMA-MARIANI TRANSMISSION LIMITED

(An Aprava Energy Company)

Registered Office: Unit No. T-15 A, Salton Has Vitas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel.: +91 11 4302 5608Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099. Tel.: +91 22 6758 8888; Fax: +91 22 6758 8811 / 8833

Website: www.aprava.com | CIN: U40102DL2016PLC403233

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025**

Kohima-Mariani Transmission Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/kohima-mariani-transmission-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debt-other/iscr/925831/debt-corp-announcements>).



Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Kohima-Mariani Transmission Limited

Sd/-
Deepa Sebastian
Director
DIN: 09443732Date: 12 November 2025
Place: Mumbai, India**JHAJJAR POWER LIMITED**

(An Aprava Energy Company)

Registered Office: Unit No. T-15 B, Salton Has Vitas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel.: +91 11 4302 5608Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099. Tel.: +91 22 6758 8888; Fax: +91 22 6758 8811 / 8833

Website: www.aprava.com | CIN: U40104DL2006PLC374107

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025**

Jhajjar Power Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (https://www.aprava.com/investor-and-compliance/investor-and-compliance_jpl) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debt-other/iscr/925011/debt-corp-announcements>).



Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Jhajjar Power Limited

Sd/-
Bhaskar Bhattacharjee
Whole-time Director
DIN: 08309161Date: 12 November 2025
Place: Mumbai, India**PHARMAIDS PHARMACEUTICALS LIMITED**

CIN: L52520KA1989PLC173079

Registered Office: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore-560013, INDIA. Tel: 080-49784319

E-mail id: compliance@pharmaids.com | Website: www.pharmaids.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER, 2025.

The Board of Pharmaids Pharmaceuticals Limited (the Company), at its Meeting held on Tuesday, November 11, 2025, approved the unaudited financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025.

The said financial results along with Limited Review Reports are available on Stock Exchange website (www.bseindia.com) and on the Company's website (<https://www.pharmaids.com/financialresults.html>). The same can be accessed by scanning the Quick Response Code provided.



Date: 11-11-2025, Place: Bengaluru

Note: The above information is in accordance with Regulations 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

By order of the Board of Directors
For Pharmaids Pharmaceuticals LimitedSd/-
Venu Madhava Kaparthi
Whole-Time Director
(DIN:00021699)**MULTIBASE INDIA LIMITED**

Regd. Off & Factory Site: 74/5-6, Daman Industrial Estate, Kalyana Village, Near Daman - 396 210 (Union Territory)

Phone: (0260) 9614400 • Fax: (0260) 2221578 • Website: www.multibaseindia.com

E-mail: compliance.officer@multibaseindia.com • CIN: L01122DD199PLC002959

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Sr. No.	Particular	Quarter ended September 30, 2025		Quarter ended June 30, 2025		Quarter ended September 30, 2024		Half year ended September 30, 2025		Half year ended September 30, 2024		Year ended March 31, 2025
		Un-Audited		Un-Audited		Un-audited		Un-Audited		Un-Audited		Audited
1	Total Income from Operations:	1,930.16	1,782.47	2,043.63	3,692.63	4,159.89	7,680.65					
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	386.39	307.83	575.70	694.22	1101.60	1969.39					
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	386.39	307.83	575.70	694.22	1101.60	1969.39					
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	298.29	229.65	428.80	515.94	821.07	1465.49					
5	Total Comprehensive Income (Comprising Profit/ (Loss) after tax and Other Comprehensive Income after tax)	298.29	229.65	428.80	515.94	821.07	1461.46					
6	Equity Share Capital (Face value of share: ₹10/-)	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00					
7	Other Equity	7,104.92	0.00	12,637.19	7,104.92	12,637.19	6,588.98					
8	Earnings per equity share in ₹											
	(i) Basic:	2.27	1.82	3.40	4.09	6.51	11.61					
	(ii) Diluted:	2.27	1.82	3.40	4.09	6.51	11.61					

Note: The above is an extract of the detailed format of unaudited financial results for the quarter and half year ended September 30, 2025 filed with BSE Ltd. under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the said quarter is available on the website of BSE Ltd. at www.bseindia.com and company's website at www.multibaseindia.com. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025.

RELOQUEMENT OF TRANSFER DEEDS

Please note that a special window has been opened for the re-lodgement of transfer deeds. This window is available for transfer deeds lodged before the deadline of April 01, 2019, which were rejected, returned, or unattended due to deficiencies in the documents, processes, or other reasons. This special window will remain open for six months, from July 07, 2025, until January 06, 2026.

SAKSHAM NIVESHAK

Multibase India Limited is proud to support the IEPFA Saksham Niveshak 100-Day Campaign an initiative designed to help investors reclaim forgotten shares and unclaimed dividends. If you or someone you know has lost track of physical share certificates or dividends, now is the time to act.

Place: Mumbai
Date: November 12, 2025

For Multibase India Limited
Sd/-
Pankaj Kumar Holani
(Managing Director)
(DIN 10843892)

Eris

ERIS LIFESCIENCES LIMITED

Regd. Office: Shivarth Ambli, Plot No. 142/2, Ramdas Road Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat-380054. Email: compliance.officer@erislifesciences.com Website: www.eris.co.in. Tel.: +91 79 6966 1000, Fax: +91 79 6966 1155, CIN: L24232GJ2007PLC049867

EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Particulars	[₹ in crores except per share data]					
	For Quarter Ended (Unaudited)		For Quarter Ended (Unaudited)		For Quarter Ended (Unaudited)	
	September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2024	September 30, 2024	March 31, 2025
Revenue from Operations	792.41	773.00	741.17	1,565.41	1,460.89	2,893.84
Net Profit for the period before tax and exceptional items	172.67	161.10	129.21	333.77	244.73	488.87
Net Profit for the period before tax and after exceptional items	172.67	161.10	129.21	333.77	244.73	488.87
Net Profit for the period after tax	134.47	125.10	95.41	259.57	185.96	374.67
Total Comprehensive Income for the period after tax	133.90	124.53	96.25	258.43	185.01	371.38
Equity Share Capital (Face Value of ₹1 each)	13.62	13.62	13.61	13.62	13.61	13.62
Other Equity	3,077.54	2,960.97	2,797.87	3,077.54	2,757.87	2,840.74
Net Worth	3,093.48	3,399.10	3,177.34	3,093.48	3,177.34	3,271.76
Paid-up Debt Capital/Outstanding Debt	2,334.37	2,448.61	2,695.24	2,334.37	2,695.24	2,421.86
Outstanding Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
Debt Equity Ratio	0.68	0.74	0.86	0.68	0.85	0.76
Earnings Per Share (of ₹1 each) (not annualised) :						
Basic	8.82	8.66	6.73	17.49	12.84	25.85
Diluted	8.81	8.64	6.72	17.46	12.82	25.81
Capital Redemption Reserve	0.17	0.17	0.17	0.17	0.17	0.17
Debitum Redemption Reserve	-	-	-	-	-	-
Debit Service Coverage Ratio	2.65	2.60	2.15	2.63	2.18	2.24
Interest Service Coverage Ratio	4.48	4.29	3.17	4.39	3.04	3.11

Notes:
1 Summary of standalone financial results of Eris Lifesciences Limited:

Particulars	[₹ in crores except per share data]					
	For Quarter Ended (Unaudited)		For Quarter Ended (Unaudited)		For Quarter Ended (Unaudited)	
	September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025
Revenue from Operations	650.50	578.64	436.56	1,229.14	893.25	1,697.75
Profit before tax	234.67	156.26	46.02	390.93	72.84	120.05
Profit after tax	149.57	99.59	28.10	249.56	45.14	77.39
Total Comprehensive Income (after tax)	149.07	99.49	27.99	248.56	44.31	74.55

2 The above is an extract of the detailed format of quarterly financial results filed with the stock exchange under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the stock exchanges websites (www.nseindia.com and www.bseindia.com) and on the company's website www.eris.co.in.
3 For the other items referred in Regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to the Stock Exchange (www.nseindia.com and www.bseindia.com) and can be accessed on the company's website www.eris.co.in.
4 The above results were reviewed by the Audit Committee and approved by the Board at their meeting held on November 12, 2025.

For Eris Lifesciences Limited
Sd/-
Chairman and Managing Director

Adhesh HCT-23

EAST COAST RAILWAY

e-tender notice No. STCR/CP/2025-26/0118, Date: 07.11.2025

NAME OF WORK: SUPPLY, INSTALLATION, TESTING & COMMISSIONING OF NEW ELECTRICAL INTERLOCKING (NOT-STANDBY) WITH DISTRIBUTED ARCHITECTURE AT GATE JUNCTION (G.J.) DUVVADA (D.V.) AND GOPALPATNAM (GPT) STATIONS AND SUPPLY, INSTALLATION, TESTING & COMMISSIONING OF ALTERATION IN EXISTING ELECTRICAL INTERLOCKING (DISTRIBUTED) OF MID KYDAN AT DUVVADA (D.V.) STATION IN CONNECTION WITH "A" & "C" LINE BETWEEN VADAPUR-GATE JUNCTION & DUVVADA-GOPALPATNAM SECTIONS INCLUDING UTILITY SHIFTING OF INFRASTRUCTURE CROSSING GATE, CABLES, LOCATION BOXES, OTHER SIGNALING & TELECOMMUNICATION GEARS" IN WALTARI DIVISION OF EAST COAST RAILWAY.

Approx. Cost of the Work: ₹13,33,27,814.95, EMD: ₹13,16,60,000. Completion Period of the Work: 18 (Eighteen) Months.

Tender Closing Date & Time: 01.11.2025, 11:00 AM.

No interest offers sent by Post / Courier / Fax or in person shall be accepted against such a tender event if there is no time to file a tender and received in time. All such interest offers shall be considered invalid and shall be rejected summarily without any consideration.

Complete information including e-tender documents of the above tender is available in website: www.epc.gov.in.

Note: The prospective bidders are advised to visit the website 15 (Fifteen) days before the date of closing of tender to note any change in / corrigendum to the tender. The bidders/bidders must have Class-D Digital Signature Certificate and must be registered on IEPFA Portal. Only registered bidder/bidders can participate in a tender.

The bidders should read all instructions to the bidders carefully and ensure compliance of all instructions including check lists, para 2.1 (additional check-list of tender form) (Second sheet) Annexure of chapter 2 of tender documents.

By Chief Signal & Telecom Engineer, PB-18/C/25-26 (C/20/Koraput)

LAXMI DENTAL LIMITED

(Formerly known as Laxmi Dental Export Private Limited)

CIN: L51507MH2004PLC147941

Registered Office: OFFICE NO. 103, AKRUTI ARCADE, 1st FLOOR, OPPOSITE A.H. WALIA HIGHER SCHOOL, ANDHERI WEST, MUMBAI, MAHARASHTRA, INDIA, 400058Tel: +91 - 22 - 6443 7991 E-mail: co.ase@laxmidentallimited.com Website: www.laxmidentallimited.com

EXTRACTS OF THE UNAUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

(₹ in Millions)

Particulars	Consolidated						Standalone					
	Quarter ended		Half Year ended		Year Ended		Quarter ended		Half Year ended		Year Ended	
	September 30, 2025 (Unaudited)	June 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	March 31, 2025 (Unaudited)	September 30, 2025 (Unaudited)	June 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	March 31, 2025 (Unaudited)
1 Total Income from operations	722.65	655.97	571.19	1,378.62	1,167.80	2,391.08	542.57	501.12	419.83	1,043.70	852.17	1,712.43
2 Net Profit for the period (before Tax, Exceptional and/or Extraordinary Items)	94.22	95.95	48.77	190.17	144.86	248.02	72.75	89.96	25.39	162.71	85.64	173.27
3 Net Profit for the period before tax (after Exceptional and/or Extraordinary Items)	94.22	95.95	48.77	190.17	211.03	318.29	72.75	89.96	25.39	162.71	151.81	243.54
4 Net Profit for the period after tax (after Exceptional and/or Extraordinary Items)	85.32	83.30	58.95	168.62	227.39	318.34	65.70	78.59	37.96	144.29	183.84	257.75
5 Total Comprehensive Income (after tax)	87.35	82.46	59.83	169.81	227.17	313.00	64.33	77.22	36.38	141.55	182.26	252.27
6 Equity Share Capital (Face Value ₹2 each)	109.92	109.92	55.63	109.92	55.63	109.92	109.92	109.92	55.63	109.92	55.63	109.92
7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	1,975.45	-	-	-	-	-	2,117.45
8 Earning Per Share of ₹2 each (before and after extraordinary items)												
Basic:	1.59	1.53	1.14	3.12	4.39	6.07	1.20	1.43	0.73	2.63	3.55	4.92
Diluted:	1.58	1.52	1.14	3.10	4.39	6.05	1.19	1.42	0.73	2.61	3.55	4.91

Notes:

a. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 11, 2025.
b. The above is an extract of the detailed format of the Consolidated and Standalone Financial Results for the quarter and half year ended September 30, 2025 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the websites of the Company, National Stock Exchange of India Limited and BSE Limited at www.laxmidentallimited.com

KOHIMA-MARIANI TRANSMISSION LIMITED

(An Aprava Energy Company)

Registered Office: Unit No. T-15/A, Saloon Ras Vihar, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel.: +91 11 4302 5608

Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099.

Tel.: +91 22 6758 8888; Fax: +91 22 6758 8811 / 8833
Website: www.aprava.com | CIN: U40102DL2006PLC043233**STATEMENT OF UNAUDITED FINANCIAL RESULTS
FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025**

Kohima-Mariani Transmission Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, *inter alia*, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/kohima-mariani-transmission-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debt-offer/scpcode/9758311/debt-corp-announcements/>).



Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Kohima-Mariani Transmission Limited

Sd/-
Deepa Sebastian
Director
DIN: 09443732Date: 12 November 2025
Place: Mumbai, India**JHAJJAR POWER LIMITED**

(An Aprava Energy Company)

Registered Office: Unit No. T-15/B, Saloon Ras Vihar, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel.: +91 11 4302 5608

Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099.

Tel.: +91 22 6758 8888; Fax: +91 22 6758 8811 / 8833
Website: www.aprava.com | CIN: U40104DL2006PLC374107**STATEMENT OF UNAUDITED FINANCIAL RESULTS
FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025**

Jhajjar Power Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, *inter alia*, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/jhajjar-power-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debt-offer/scpcode/952011/debt-corp-announcements/>).



Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Jhajjar Power Limited

Sd/-
Bhaskar Bhattacharjee
Whole-time Director
DIN: 08309161Date: 12 November 2025
Place: Mumbai, India**PHARMAIDS PHARMACEUTICALS LIMITED**

CIN: L52520KA1989PLC173979

Registered Office: Unit #201, Brigade Rubix, 20/14, HMT Factory Road,

Peenya Plantation, Bangalore-560013, INDIA. Tel: 080-49784319

E-mail: id: compliance@pharmaids.com | Website: www.pharmaids.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER, 2025.

The Board of Pharmaids Pharmaceuticals Limited (the "Company"), at its Meeting held on Tuesday, November 11, 2025, approved the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025.

The said financial results along with Limited Review Reports are available on Stock Exchange website (www.bseindia.com) and on the Company's website (<https://www.pharmaids.com/financialresults.html>). The same can be accessed by scanning the Quick Response Code provided.

By order of the Board of Directors
For Pharmaids Pharmaceuticals LimitedSd/-
Venu Madhava Kapatthy
Whole-Time Director
(DIN:00021699)

Date: 11-11-2025, Place: Bengaluru

Note: The above intimation is in accordance with Regulations 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**MULTIBASE INDIA LIMITED**

Regd. Off & Factory Site: 74/5-6, Daman Industrial Estate, Kalyani Village, Nani Daman - 396 210 (Union Territory)

Phone: (0260) 6614400 • Fax: (0260) 2221578 • Website: www.multibaseindia.com

E-mail: compliance.officer@multibaseindia.com • CIN: L01122DD1991PLC002959

**EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025**

		Quarter Ended				Half-year Ended		(₹ in lakhs)
Sr. No.	Particular	Quarter ended	Quarter ended	Quarter ended	Half year ended	Half year ended	Year ended	
		September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025	
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited	
1	Total Income from Operations:	1,930.16	1,762.47	2,043.63	3,692.63	4,159.89	7,680.65	
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items):	386.39	307.83	575.70	694.22	1,101.60	1969.39	
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items):	386.39	307.83	575.70	694.22	1,101.60	1969.39	
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items):	286.29	229.65	428.80	515.94	821.07	1465.49	
5	Total Comprehensive Income (Comprising Profit/ (Loss) after tax and Other Comprehensive Income after tax)	286.29	229.65	428.80	515.94	821.07	1461.46	
6	Equity Share Capital (Face value of share: ₹10/-)	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00	
7	Other Equity	7,104.92	0.00	12,637.19	7,104.92	12,637.19	6,588.98	
8	Earnings per equity share in ₹							
	(i) Basic:	2.27	1.82	3.40	4.09	6.51	11.61	
	(ii) Diluted:	2.27	1.82	3.40	4.09	6.51	11.61	

Note: The above is an extract of the detailed format of unaudited financial results for the quarter and half year ended September 30, 2025 filed with BSE Ltd. under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the said quarter is available on the website of BSE Ltd. at www.bseindia.com and company's website at www.multibaseindia.com. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025.

RECOGNITION OF TRANSFER DEEDS

Please note that a special window has been opened for the re- lodgement of transfer deeds. This window is available for transfer deeds lodged before the deadline of April 01, 2019, which were rejected, returned, or unattended due to deficiencies in the documents, processes, or other reasons. This special window will remain open for six months, from July 07, 2025, until January 06, 2026.

SAKSHAM NEVESHAK

Multibase India Limited is proud to support the IEPFA Saksham Neveshak 100-Day Campaign an initiative designed to help investors reclaim forgotten shares and limited dividends. If you or someone you know has lost track of physical share certificates or dividends, now is the time to act.

Place: Mumbai

Date: November 12, 2025

Scan me!

For Multibase India Limited
Sd/-
Pankaj Kumar Holani
(Managing Director)
(DIN 10843892)**Eris
ERIS LIFESCIENCES LIMITED**Regd. Office: Shivarth Ambit, Plot No 142/2, Ramdas Road Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat-380054. Email: complianceofficer@erislifesciences.com Website: www.eris.co.in.
Tel: +91 79 6966 1000, Fax: +91 79 6966 1155, CIN: L24323GJ2007PLC049867**EXTRACT OF CONSOLIDATED FINANCIAL RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025**

	[₹ in crores except per share data]					
Particulars	For Quarter (Unaudited)	For Quarter (Unaudited)	For Quarter (Unaudited)	For Half Year (Unaudited)	For Half Year (Unaudited)	For Year (Audited)
	September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025
Revenue from Operations	792.41	773.00	741.17	1,565.41	1,460.89	2,893.64
Net Profit for the period before tax and exceptional items	172.67	161.10	129.21	333.77	244.73	488.87
Net Profit for the period before tax and after exceptional items	172.67	161.10	129.21	333.77	244.73	488.87
Net Profit for the period after tax	134.47	125.10	96.41	259.57	185.96	374.67
Total Comprehensive Income for the period after tax	133.90	124.53	96.25	258.43	185.01	371.38
Equity Share Capital (Face Value of ₹1 each)	13.62	13.62	13.61	13.62	13.61	13.62
Other Equity	3,077.54	2,960.97	2,757.87	3,077.54	2,757.87	2,840.74
Net Worth	3,503.48	3,399.10	3,177.34	3,503.48	3,177.34	3,271.76
Paid-up Debt Capital/Outstanding Debt	2,334.37	2,448.61	2,695.24	2,334.37	2,695.24	2,421.66
Outstanding Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
Debt Equity Ratio	0.68	0.74	0.86	0.68	0.86	0.76
Earnings Per Share (of ₹1 each) (not annualised) :						
Basic	8.82	8.66	6.73	17.49	12.84	25.85
Diluted	8.81	8.64	6.72	17.46	12.82	25.81
Capital Redemption Reserve	0.17	0.17	0.17	0.17	0.17	0.17
Debiture Redemption Reserve	-	-	-	-	-	-
Debt Service Coverage Ratio	2.85	2.60	2.15	2.63	2.18	2.24
Interest Service Coverage Ratio	4.48	4.29	3.17	4.39	3.04	3.11

Notes:
1. Summary of standalone financial results of Eris Lifesciences Limited:

Summary of standalone financial results of Eris Lifesciences Limited							[7 in crores except per share data]				
Particulars	For Quarter Ended (Unaudited)		For Quarter Ended (Unaudited)		For Quarter Ended (Unaudited)		For Half Year Ended (Unaudited)		For Half Year Ended (Unaudited)		For Year Ended (Audited)
	September 30, 2025	June 30, 2025	September 30, 2025	June 30, 2024	September 30, 2025	September 30, 2025	September 30, 2025	September 30, 2024	September 30, 2024	March 31, 2025	
Revenue from Operations	650.50	578.64	436.56	1,229.14	893.25	1,697.75					
Profit before tax	234.67	156.26	46.02	390.93	72.84	120.05					
Profit after tax	149.57	99.99	28.10	249.56	45.14	77.39					
Total Comprehensive Income (after tax)	148.07	99.49	27.99	248.56	44.31	74.55					

2 The above is an extract of the detailed format of quarterly financial results filed with the stock exchange under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the stock exchanges websites (www.nseindia.com) and www.bseindia.com and on the company's website www.eris.co.in.

For the other line items referred in Regulation 52(4) of the Listing Regulations, pertinent disclosures have been made in the Stock Exchange(s) (www.nseindia.com) and www.bseindia.com) and can be accessed on the company's website www.eris.co.in.

The above results were reviewed by the Audit Committee and accounted by the Board at their meeting held on November 12, 2025.

2. The above is an extract of the detailed format of quarterly financial results filed with the stock exchange under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the company's website (www.eris.co.in) and on the company's website www.eris.co.in.3. For the other line items referred in Regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to the Stock Exchange(s) (www.nseindia.com) and (www.bseindia.com) and can be accessed on the company's website www.eris.co.in.

4. The above results were reviewed by the Audit Committee and approved by the Board at their meeting held on November 12, 2025.

For Eris Lifesciences Limited
Sd/-
Chairman and Managing Director

Attested 06/12/25

Place: Ahmedabad
Date: November 12, 2025**EAST COAST RAILWAY**

e-Tender Notice No. STCRP/UP-VG-

B-2-OT/11, Date: 07.11.2025

NAME OF WORK: SUPPLY

INSTALLATION, TESTING &

COMMISSIONING OF NEW

ELECTRONIC INTERLOCKING (NOT

STANDBY) WITH DISTRIBUTION

ARCHITECTURE AT GATE JUNCTION

(G.J.), DUVVADA (D.V.) AND

GOPALPATNAM (G.P.T) STATIONS

AND SUPPLY, INSTALLATION, DESIGN

& COMMISSIONING OF ALTERNATE

IN EXISTING ELECTRONIC

INTERLOCKING (DISTRIBUTION)

OF MIS KYOSAN AT VADAPUDI (VDP)

STATION IN CONNECTION WITH 'A'

'4' LINE BETWEEN VADAPUDI-GATE

JUNCTION AND DUVVADA-

GOPALPATNAM SECTIONS AND

PROVISION OF AUTOMATIC BLOCK

WORKING BETWEEN VADAPUDI-
GATE JUNCTION & DUVVADA-
GOPALPATNAM SECTION
INCLUDING UTILITY SHIFTING OF
INFERRING LEVEL CROSSING GATE,
CABLES, LOCATION BOXES, OTHER
SIGNALLING & TELECOMMUNICATION
GEAR IN WALTARI DIVISION OF
EAST COAST RAILWAY

APPLICABLE DATE OF THE WORK

18.03.27, 18.04.05, EMO: 133, 16.06.00

Completion Period of the Work: 18

(Eighteen) Months.

Tender Closing Date & Time: 1st 1530

hrs. of 12.2025.

No financial offer sent by Post / Courier /

Fax or in person shall be accepted against

this tender even if it is submitted

on time before the date of closing of tender

and shall be rejected summarily without

any consideration.

Complete information including e-tender

documents of the above tender is

available in website: www.ecr.gov.in

Note: The prospective bidders are

advised to visit the website 15 (fifteen)

days before the date of closing of tender to

note any changes / corrigenda issued for

this tender. The bidders/bidders must

have Class II Digital Signature Certificate

and must be registered on (REPS) Portal

Only registered tenderer/bidder can

participate in e-tendering.

The bidders should read all

instructions to the bidders carefully

and ensure compliance of all

instructions including check lists, para

1.5 (Additional check-list) of Tender

form (Second sheet) Annexure-I of

chapter 2 of Tender documents.

Dr. Chief Engineer & Telecom Engineer,
PR-190/CV25-28
(Gen)/Koraput**LAXMI DENTAL LIMITED**

(Formerly known as Laxmi Dental Export Private Limited)

CIN: L51507MH2004PLC147394



PHARMAIDS PHARMACEUTICALS LIMITED

CIN - L5250KA1989PLC173079

Registered Office: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore-560013, INDIA. Tel: 080-49784319
E-mail Id: compliance@pharmaids.com | Website: www.pharmaids.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER, 2025.

The Board of Pharmaids Pharmaceuticals Limited (the Company), at its Meeting held on Tuesday, November 11, 2025, approved the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025.



The said financial results along with Limited Review Reports are available on Stock Exchange website (www.bseindia.com) and on the Company's website (<https://www.pharmaids.com/financialresults.html>). The same can be accessed by scanning the Quick Response Code provided.

By order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Sd/-
Venu Madhava Kaparthu
Whole-Time Director
(DIN:00021699)

Date: 11-11-2025, Place: Bengaluru

Note: The above information is in accordance with Regulations 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

KOHIMA-MARIANI TRANSMISSION LIMITED

(An Aprava Energy Company)

Registered Office: Unit No. T-15 A, Sakon Ras Vilas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel: +91 11 4302 5608
Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099.
Tel: +91 22 6756 8888, Fax: +91 22 6756 8811 / 8833
Website: www.aprava.com | CIN: U40102DL2016PLC403233



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025

Kohima-Mariani Transmission Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/kohima-mariani-transmission-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debit-ether/qrcode/9759311debt-corp-announcements/>).



Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Kohima-Mariani Transmission Limited

Sd/-
Deepa Sebastian
Director
(DIN: 09443732)

Date: 12 November 2025
Place: Mumbai, India



MULTIBASE INDIA LIMITED

Regd. Off & Factory Site: 74/5-B, Danner Industrial Estate, Kadipalya Village, Nam Damani - 206 210 (Union Territory)
• Phone: (0260) 9614400 • Fax: (0260) 2221578 • Website: www.multibaseindia.com
• E-mail: compliance.officer@multibaseindia.com • CIN: L01122DD1991PLC002959

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Sr. No.	Particular	Quarter Ended						Half Year Ended		Year Ended
		Quarter ended September 30, 2025	Quarter ended June 30, 2025	Quarter ended September 30, 2024	Quarter ended June 30, 2024	Quarter ended September 30, 2023	Quarter ended June 30, 2023	Half year ended September 30, 2025	Half year ended June 30, 2025	Year ended March 31, 2025
1	Total Income from Operations	1,930.16	1,762.47	2,043.63	3,692.63	4,159.89	7,680.05			
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	386.39	307.83	575.70	694.22	1101.60	1969.39			
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	386.39	307.83	575.70	694.22	1101.60	1969.39			
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	296.29	229.65	428.80	515.94	821.07	1465.49			
5	Total Comprehensive Income (Comprising Profit/ (Loss) after tax and Other Comprehensive Income after tax)	296.29	229.65	428.80	515.94	821.07	1465.49			
6	Equity Share Capital (Face value of share: ₹10/-)	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00			
7	Other Equity	7,104.92	0.00	12,637.19	7,104.92	12,637.19	6,588.96			
8	Earnings per equity share in ₹									
(i) Basic:		2.37	1.82	3.40	4.08	6.51	11.81			
(ii) Diluted:		2.37	1.82	3.40	4.08	6.51	11.81			

Notes: The above is an extract of the detailed format of unaudited financial results for the quarter and half year ended September 30, 2025 filed with BSE Ltd. under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the said quarter is available on the website of BSE Ltd. (www.bseindia.com) and company's website at www.multibaseindia.com. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025.

REDEMPTION OF TRANSFER DEEDS

Please note that a special window has been opened for the re-issuance of transfer deeds. This window is available for transfer deeds lodged before the deadline of April 01, 2019, which were rejected, returned, or unattended due to deficiencies in the documents, processes, or other reasons. This special window will remain open for six months, from July 07, 2025, until January 06, 2026.

SAKSHAM NIVESHAK

Multibase India Limited is proud to support the IEPFA Saksham Niveshak 100-Day Campaign an initiative designed to help investors reclaim forgotten shares and undivided dividends. If you or someone you know has lost track of physical share certificates or dividends, now is the time to act.



For Multibase India Limited
Sd/-
Prabhakumar Halani
(Managing Director)
(DIN 10643892)

Place: Mumbai
Date: November 12, 2025

JHAJJAR POWER LIMITED

(An Aprava Energy Company)

Registered Office: Unit No. T-15 B, Sakon Ras Vilas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel: +91 11 4302 5608
Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099.
Tel: +91 22 6756 8888, Fax: +91 22 6756 8811 / 8833
Website: www.aprava.com | CIN: U40104DL2008PLC374107



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025

Jhajjar Power Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/jhajjar-power-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debit-ether/qrcode/9520311debt-corp-announcements/>).



Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Jhajjar Power Limited

Sd/-
Bhaskar Bhattacharjee
Whole-time Director
(DIN: 06309161)

Date: 12 November 2025
Place: Mumbai, India

Eris

ERIS LIFESCIENCES LIMITED

Regd. Office: Shivarth Ambit, Plot No 14/22, Ramdas Road Off SBR, Near Swasth Bungalows, Bodakdev, Ahmedabad, Gujarat-380054. Email: compliance.officer@erislifesciences.com Website: www.eris.co.in
Tel: +91 79 6966 1000, Fax: +91 79 6966 1155, CIN: L24232GJ2007PLC049867

EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Particulars	[₹ in crores except per share data]					
	For Quarter Ended (Unaudited) September 30, 2025	For Quarter Ended (Unaudited) June 30, 2025	For Quarter Ended (Unaudited) September 30, 2024	For Half Year Ended (Unaudited) September 30, 2025	For Half Year Ended (Unaudited) September 30, 2024	For Year Ended (Audited) March 31, 2025
Revenue from Operations	792.41	773.00	741.17	1,565.41	1,460.89	2,893.64
Net Profit for the period before tax and exceptional items	172.67	161.10	129.21	333.77	244.73	468.87
Net Profit for the period before tax and after exceptional items	172.67	161.10	129.21	333.77	244.73	468.87
Net Profit for the period after tax	134.47	125.10	96.41	259.57	185.96	374.67
Total Comprehensive Income for the period after tax	133.90	124.53	96.25	258.43	185.01	371.38
Equity Share Capital (Face Value of ₹1 each)	13.62	13.62	13.61	13.62	13.61	13.62
Other Equity	3,077.54	2,960.97	2,757.87	3,077.54	2,757.87	2,840.74
Net Worth	3,053.48	3,099.10	3,177.34	3,053.48	3,177.34	3,271.76
Paid-up Debt Capital/Outstanding Debt	2,334.37	2,448.61	2,695.24	2,334.37	2,695.24	2,421.66
Outstanding Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
Debt Equity Ratio	0.68	0.74	0.86	0.68	0.86	0.76
Earnings Per Share (of ₹1 each) (not annualised):						
Basic	8.82	8.66	6.73	17.49	12.84	25.85
Diluted	8.81	8.64	6.72	17.46	12.82	25.81
Capital Redemption Reserve	0.17	0.17	0.17	0.17	0.17	0.17
Debit Service Coverage Ratio	2.65	2.60	2.15	2.63	2.18	2.24
Interest Service Coverage Ratio	4.48	4.29	3.17	4.39	3.04	3.11

Notes: 1. Summary of standalone financial results of Eris Lifesciences Limited:

Particulars	[₹ in crores except per share data]					
	For Quarter Ended (Unaudited) September 30, 2025	For Quarter Ended (Unaudited) June 30, 2025	For Quarter Ended (Unaudited) September 30, 2024	For Half Year Ended (Unaudited) September 30, 2025	For Half Year Ended (Unaudited) September 30, 2024	For Year Ended (Audited) March 31, 2025
Revenue from Operations	650.50	578.64	436.56	1,229.14	893.25	1,697.75
Profit before tax	234.67	156.26	46.02	390.93	72.84	120.05
Profit after tax	149.57	99.99	28.10	249.56	45.14	77.39
Total Comprehensive Income (after tax)	149.07	99.49	27.99	248.56	44.31	74.55

2. The above is an extract of the detailed format of quarterly financial results filed with the stock exchange under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the stock exchanges websites (www.nseindia.com and www.bseindia.com) and on the company's website www.eris.co.in.

3. For the other line items referred in Regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to the Stock Exchange(s) (www.nseindia.com) and can be accessed on the company's website www.eris.co.in.

4. The above results were reviewed by the Audit Committee and approved by the Board at their meeting held on November 12, 2025.



Place: Ahmedabad
Date: November 12, 2025

For Eris Lifesciences Limited
Sd/-
Chairman and Managing Director

(Address: 607/23)



LAXMI DENTAL LIMITED

(Formerly known as Laxmi Dental Export Private Limited)

Registered Office: OFFICE NO. 103, AKRUTI ARCADE, J.P. ROAD, OPPOSITE A.H. WADIA HIGH SCHOOL, ANDHERI WEST, MUMBAI, MAHARASHTRA, INDIA, 400058
Tel: +91 - 22 - 6143 7991 E-mail: co.se@laxmidentallimited.com Website: www.laxmidentallimited.com

EXTRACTS OF THE UNAUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

(Rs in Millions)

Particulars	Consolidated						Standalone					
	Quarter ended			Half Year ended			Quarter ended			Half Year ended		
	September 30, 2025 (Unaudited)	June 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	March 31, 2025 (Audited)	September 30, 2025 (Unaudited)	June 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	March 31, 2025 (Audited)
1 Total Income from operations	722.65	655.97	571.19	1,378.62	1,167.80	2,391.08	542.57	501.12	419.83	1,043.70	852.17	1,712.43
2 Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	94.22	95.95	48.77	190.17	144.86	248.02	72.75	89.96	25.39	162.71	85.64	173.27
3 Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	94.22	95.95	48.77	190.17	211.03	318.29	72.75	89.96	25.39	162.71	151.81	243.54
4 Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	85.32	83.30	58.95	168.62	227.39	318.34	65.70	78.59	37.96	144.29	183.84	257.75
5 Total Comprehensive Income (after tax)	87.35	82.46	59.83	169.81	227.17	313.00	64.33	77.22	36.38	141.55	182.26	252.27
6 Equity Share Capital (Face Value Rs 2 each)	109.92	109.92	55.63	109.92	55.63	109.92	109.92	109.92	55.63	109.92	55.63	109.92
7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	1,975.45	-	-	-	-	-	2,117.45
8 Earning Per Share of Rs 2 each (before and after extraordinary items)												
Basic:	1.59	1.53	1.14	3.12	4.39	6.07	1.20	1.43	0.73	2.63	3.55	4.92
Diluted:	1.58	1.52	1.14	3.10	4.39	6.05	1.19	1.42	0.73	2.61	3.55	4.91

Notes:

a. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 11, 2025.
b. The above is an extract of the Audited format of the Consolidated and Standalone Financial Results for the quarter and half year ended September 30, 2025 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the websites of the Company, National Stock Exchange of India Limited and BSE Limited at www.laxmidentallimited.com, www.nseindia.com and www.bseindia.com, respectively.

Place: Mumbai
Date: November 11, 2025



For and on behalf of the Board of Directors
Sd/-
Sanjeev Kamlesh Merchant
CEO & Managing Director
(DIN: 00679893)

PHARMAIDS PHARMACEUTICALS LIMITED
CIN - L52520KA1989PLC173079
Registered Office: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore-560013, INDIA. Tel: 080-49784319
E-mail id: compliance@pharmaids.com | Website: www.pharmaids.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER, 2025.

The Board of Pharmaids Pharmaceuticals Limited ('the Company'), at its Meeting held on Tuesday, November 11, 2025, approved the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025.

The said financial results along with Limited Review Reports are available on Stock Exchange website (www.bseindia.com) and on the Company's website (<https://www.pharmaids.com/financialresults.html>). The same can be accessed by scanning the Quick Response Code provided.

By order of the Board of Directors
For Pharmaids Pharmaceuticals Limited
Sd/-
Venu Madhava Kaparthu
Whole-Time Director
(DIN:00021699)

Date: 11-11-2025, Place: Bengaluru
Note: The above information is in accordance with Regulations 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

KOHIMA-MARIANI TRANSMISSION LIMITED
(An Aprava Energy Company)
Registered Office: Unit No. T-15 A, Saloon Ras Vitas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel.: +91 11 4302 5608
Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099.
Tel.: +91 22 6758 8888, Fax: +91 22 6758 8811 / 8833
Website: www.aprava.com | CIN: U40102DL2016PLC403233



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025

Kohima-Mariani Transmission Limited ('the Company') hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ('Results') along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ('QR Code') given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/kohima-mariani-transmission-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debt-other/corporate/952011/debt-corp-announcements>).

For and on behalf of Board of Directors of Kohima-Mariani Transmission Limited
Sd/-
Deepa Sebastian
Director
DIN: 09443732
Date: 12 November 2025
Place: Mumbai, India

Scan the QR Code to view the Results on the website of the Company

Scan the QR Code to view the Results on the website of BSE Limited

MULTIBASE INDIA LIMITED
Regd. Off & Factory Site: 74/5-6, Damsel Industries Estate, Kodiyas Village, Nani Daman - 396 210 (Union Territory)
• Phone: (0269) 9614400 • Fax: (0269) 2221578 • Website: www.multibaseindia.com
• E-mail: compliance.officer@multibaseindia.com • CIN: L01122DD1991PLC002969

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Sr. No.	Particular	Quarter Ended						Half-Year Ended		Year Ended
		Quarter ended September 30, 2025	Quarter ended June 30, 2025	Quarter ended September 30, 2024	Quarter ended June 30, 2024	Quarter ended September 30, 2023	Quarter ended June 30, 2023	Half year ended September 30, 2025	Half year ended June 30, 2025	Year ended March 31, 2025
1	Total Income from Operations	1,930.16	1,762.47	2,043.63	3,692.63	4,159.89	7,880.65			
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	386.39	307.83	575.70	694.22	1101.60	1969.39			
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	386.39	307.83	575.70	694.22	1101.60	1969.39			
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	286.29	229.65	428.80	515.94	821.07	1465.49			
5	Total Comprehensive Income (Comprising Profit / (Loss) after tax and Other Comprehensive Income after tax)	286.29	229.65	428.80	515.94	821.07	1465.49			
6	Equity Share Capital (Face value of share: ₹10/-)	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00			
7	Other Equity	7,104.92	0.00	12,637.19	7,104.92	12,637.19	6,588.96			
8	Earnings per equity share in ₹	2.27	1.82	3.40	4.88	8.51	11.81			
9	Diluted	2.27	1.82	3.40	4.88	8.51	11.81			

Note: The above is an extract of the detailed format of unaudited financial results for the quarter and nine months ended September 30, 2025 filed with BSE Ltd. under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the said quarter is available on the website of BSE Ltd. at www.bseindia.com and company's website at www.multibaseindia.com. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025.

RELINQUISHMENT OF TRANSFER DEEDS
Please note that a special window has been opened for the relinquishment of transfer deeds. This window is available for transfer deeds lodged before the deadline of April 01, 2019, which were rejected, returned, or unattended due to deficiencies in the documents, processes, or other reasons. This special window will remain open for six months, from July 07, 2025, until January 06, 2026.

SAKSHAM NIVESHAK
Multibase India Limited is proud to support the IEPFA Saksham Niveshak 100-Day Campaign an initiative designed to help investors reclaim forgotten shares and unclaimed dividends. If you or someone you know has lost track of physical share certificates or dividends, now is the time to act.

For Multibase India Limited
Sd/-
Pankaj Kumar Holani
(Managing Director)
(DIN 10643892)
Place: Mumbai
Date: November 12, 2025

JHAJJAR POWER LIMITED

(An Aprava Energy Company)

Registered Office: Unit No. T-15 B, Saloon Ras Vitas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel.: +91 11 4302 5608
Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099.
Tel.: +91 22 6758 8888, Fax: +91 22 6758 8811 / 8833
Website: www.aprava.com | CIN: U40104DL2008PLC374107

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025

Jhajjar Power Limited ('the Company') hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ('Results') along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ('QR Code') given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/jhajjar-power-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debt-other/corporate/952011/debt-corp-announcements>).

For and on behalf of Board of Directors of Jhajjar Power Limited
Sd/-
Bhaskar Bhattacharjee
Whole-time Director
DIN: 06309161
Date: 12 November 2025
Place: Mumbai, India

Scan the QR Code to view the Results on the website of the Company

Scan the QR Code to view the Results on the website of BSE Limited

Eris

ERIS LIFESCIENCES LIMITED

Regd. Office: Shivarth Ambli, Plot No 142/2, Ramdas Road Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat-380054. Email: compliance.officer@erislifesciences.com Website: www.eris.co.in,
Tel.: +91 79 6966 1000, Fax: +91 79 6966 1155, CIN: L24232GJ2007PLC049867

EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Particulars	For Quarter Ended (Unaudited) September 30, 2025	For Quarter Ended (Unaudited) June 30, 2025	For Quarter Ended (Unaudited) September 30, 2024	For Half Year Ended (Unaudited) September 30, 2025	For Half Year Ended (Unaudited) September 30, 2024	For Year Ended (Audited) March 31, 2025
	September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025
Revenue from Operations	792.41	773.00	741.17	1,565.41	1,460.89	2,893.64
Net Profit for the period before tax and exceptional items	172.67	161.10	129.21	333.77	244.73	488.87
Net Profit for the period before tax and after exceptional items	172.67	161.10	129.21	333.77	244.73	488.87
Net Profit for the period after tax	134.47	125.10	96.41	259.57	165.96	374.67
Total Comprehensive Income for the period after tax	133.90	124.53	96.25	258.43	165.01	371.38
Equity Share Capital (Face Value of ₹1 each)	13.62	13.62	13.61	13.62	13.61	13.62
Other Equity	3,077.54	2,960.97	2,757.87	3,077.54	2,757.87	2,840.74
Net Worth	3,053.48	3,399.10	3,177.34	3,503.48	3,177.34	3,271.76
Paid-up Debt Capital/Outstanding Debt	2,334.37	2,448.61	2,695.24	2,334.37	2,695.24	2,421.66
Outstanding Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
Debt Equity Ratio	0.68	0.74	0.86	0.68	0.86	0.76
Earnings Per Share (of ₹1 each) (not annualised) :						
Basic	8.82	8.86	6.73	17.49	12.84	25.85
Diluted	8.61	8.64	6.72	17.46	12.82	25.81
Capital Redemption Reserve	0.17	0.17	0.17	0.17	0.17	0.17
Debt Redemption Reserve	-	-	-	-	-	-
Debt Service Coverage Ratio	2.65	2.60	2.15	2.63	2.18	2.24
Interest Service Coverage Ratio	4.48	4.29	3.17	4.39	3.04	3.11

Notes:
1. Summary of standalone financial results of Eris Lifesciences Limited:

Particulars	For Quarter Ended (Unaudited) September 30, 2025	For Quarter Ended (Unaudited) June 30, 2025	For Quarter Ended (Unaudited) September 30, 2024	For Half Year Ended (Unaudited) September 30, 2025	For Half Year Ended (Unaudited) September 30, 2024	For Year Ended (Audited) March 31, 2025
	September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025
Revenue from Operations	650.50	578.64	436.56	1,229.14	803.25	1,697.75
Profit before tax	234.67	156.26	46.02	390.93	72.84	120.05
Profit after tax	149.57	99.99	28.10	249.56	45.14	77.39
Total Comprehensive Income (after tax)	149.07	99.49	27.99	248.56	44.31	74.55

2. The above is an extract of the detailed format of quarterly financial results filed with the stock exchange under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the stock exchanges websites (www.bseindia.com and www.nseindia.com) and on the company's website www.eris.co.in.
3. For the other line items referred in Regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to the Stock Exchange(s) (www.bseindia.com and www.nseindia.com) and can be accessed on the company's website www.eris.co.in.
4. The above results were reviewed by the Audit Committee and approved by the Board at their meeting held on November 12, 2025.

For Eris Lifesciences Limited
Sd/-
Chairman and Managing Director
Place: Ahmedabad
Date: November 12, 2025

Scan me!

Autodesk iCt-23

LAXMI DENTAL LIMITED
(Formerly known as Laxmi Dental Export Private Limited)
(CIN: L51507MH2004PLC147394)
Registered Office: OFFICE NO. 103, AKRUTI ARCADE, J.P. ROAD, OPPOSITE A.H. WADIA HIGH SCHOOL, ANDHERI WEST, MUMBAI, MAHARASHTRA, INDIA, 400058
Tel.: +91 22 6143 7991 E-mail: co.scrip@laxmidental.com Website: www.laxmidental.com

EXTRACTS OF THE UNAUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

(Rs in Millions)

Particulars	Consolidated						Standalone					
	Quarter ended September 30, 2025 (Unaudited)	Quarter ended June 30, 2025 (Unaudited)	Quarter ended September 30, 2024 (Unaudited)	Quarter ended June 30, 2024 (Unaudited)	Quarter ended September 30, 2023 (Unaudited)	Quarter ended June 30, 2023 (Unaudited)	Quarter ended September 30, 2025 (Unaudited)	Quarter ended June 30, 2025 (Unaudited)	Quarter ended September 30, 2024 (Unaudited)	Quarter ended June 30, 2024 (Unaudited)	Quarter ended September 30, 2023 (Unaudited)	Quarter ended June 30, 2023 (Unaudited)
1. Total Income from operations	722.65	655.97	571.19	1,378.62	1,167.80	2,391.08	542.57	501.12	419.83	1,043.70	852.17	1,712.43
2. Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	94.22	95.95	48.77	190.17	144.86	248.02	72.75	89.96	25.39	162.71	85.64	173.27
3. Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	94.22	95.95	48.77	190.17	211.03	318.29	72.75	89.96	25.39	162.71	151.81	243.54
4. Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	85.32	83.30	58.95	168.62	227.39	318.34	65.70	78.59	37.96	144.29	183.84	257.75
5. Total Comprehensive Income (after tax)	87.35	82.46	59.83	169.81	227.17	313.00	64.33	77.22	36.38	141.55	182.26	252.27
6. Equity Share Capital (Face Value ₹2 each)	109.92	109.92	55.63	109.92	55.63	109.92	109.92	109.92	55.63	109.92	55.63	109.92
7. Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	1,975.45	-	-	-	-	-	2,117.45
8. Earning Per Share of ₹2 each (before and after extraordinary items)	1.59	1.53	1.14	3.12	4.39	6.07	1.26	1.43	0.73	2.63	3.55	4.92
Diluted:	1.58	1.52	1.14	3.10	4.39	6.05	1.19	1.42	0.73	2.61	3.55	4.91

Notes:
a. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 11, 2025.
b. The above is an extract of the detailed format of the Consolidated and Standalone Financial Results for the quarter and half year ended September 30, 2025 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the websites of the Company, National Stock Exchange of India Limited and BSE Limited at www.laxmidental.com, www.nseindia.com and www.bseindia.com, respectively.

For and on behalf of the Board of Directors
Sd/-
Samer Kamlesh Merchant
CEO & Managing Director
DIN: 06679893
Place: Mumbai
Date: November 11, 2025



PHARMAIDS PHARMACEUTICALS LIMITED

CIN - L5250KA1989PLC173079

Registered Office: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore-560013, INDIA. Tel: 080-49784319
E-mail Id: compliance@pharmalids.com | Website: www.pharmalids.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER, 2025.

The Board of Pharmalids Pharmaceuticals Limited (the Company), at its Meeting held on Tuesday, November 11, 2025, approved the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025.



The said financial results along with Limited Review Reports are available on Stock Exchange website (www.bseindia.com) and on the Company's website (<https://www.pharmalids.com/financialresults.html>). The same can be accessed by scanning the Quick Response Code provided.

By order of the Board of Directors
For Pharmalids Pharmaceuticals Limited

Sd/-
Venu Madhava Kaparthu

Whole-Time Director
(DIN:00021699)

Date: 11-11-2025, Place: Bengaluru

Note: The above information is in accordance with Regulations 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

KOHIMA-MARIANI TRANSMISSION LIMITED

(An Aprava Energy Company)

Registered Office: Unit No. T-15 A, Sakon Ras Vilas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel: +91 11 4302 5608
Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099.
Tel: +91 22 6758 8888, Fax: +91 22 6758 8811 / 8833
Website: www.aprava.com | CIN: U40102DL2016PLC403233



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025

Kohima-Mariani Transmission Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/kohima-mariani-transmission-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debit-ether/qrcode/9759311/debit-corp-announcements>).



Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Kohima-Mariani Transmission Limited

Sd/-
Deepa Sebastian

Director
(DIN: 09443732)

Date: 12 November 2025
Place: Mumbai, India



MULTIBASE INDIA LIMITED

Regd. Off & Factory Site: 74/5-B, Danner Industrial Estate, Kadipalya Village, Nam Damani - 206 210 (Union Territory)

• Phone: (0260) 9614400 • Fax: (0260) 2221578 • Website: www.multibaseindia.com

• E-mail: compliance.officer@multibaseindia.com • CIN: L01122DD1991PLC002959

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Sr. No.	Particular	Quarter Ended						Half Year Ended		Year Ended
		Quarter ended September 30, 2025	Quarter ended June 30, 2025	Quarter ended September 30, 2024	Quarter ended June 30, 2024	Quarter ended September 30, 2023	Quarter ended June 30, 2023	Half year ended September 30, 2025	Half year ended June 30, 2025	Year ended March 31, 2025
1	Total Income from Operations	1,930.16	1,762.47	2,043.63	3,692.63	4,159.89	7,880.05			
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	386.39	307.83	575.70	694.22	1101.60	1969.39			
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	386.39	307.83	575.70	694.22	1101.60	1969.39			
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	296.29	229.65	428.80	515.94	821.07	1465.49			
5	Total Comprehensive Income (Comprising Profit / (Loss) after tax and Other Comprehensive Income after tax)	296.29	229.65	428.80	515.94	821.07	1465.49			
6	Equity Share Capital (Face value of share: ₹10/-)	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00			
7	Other Equity	7,104.92	0.00	12,637.19	7,104.92	12,637.19	6,588.96			
8	Earnings per equity share in ₹									
(i) Basic		2.37	1.82	3.40	4.08	6.51	11.81			
(ii) Diluted		2.37	1.82	3.40	4.08	6.51	11.81			

Notes: The above is an extract of the detailed format of unaudited financial results for the quarter and nine months ended September 30, 2025 filed with BSE Ltd. under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the said quarter is available on the website of BSE Ltd. (www.bseindia.com) and company's website at www.multibaseindia.com. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025.

REDEMPTION OF TRANSFER DEEDS

Please note that a special window has been opened for the re-issuance of transfer deeds. This window is available for transfer deeds lodged before the deadline of April 01, 2019, which were rejected, returned, or unattended due to deficiencies in the documents, processes, or other reasons. This special window will remain open for six months, from July 07, 2025, until January 06, 2026.

SAKSHAM NIVESHAK

Multibase India Limited is proud to support the IEPFA Saksham Niveshak 100-Day Campaign an initiative designed to help investors reclaim forgotten shares and undivided dividends. If you or someone you know has lost track of physical share certificates or dividends, now is the time to act.



For Multibase India Limited
Sd/-
Prabhakumar Halani

(Managing Director)
(DIN 10643892)

Place: Mumbai
Date: November 12, 2025

JHAJJAR POWER LIMITED

(An Aprava Energy Company)

Registered Office: Unit No. T-15 B, Sakon Ras Vilas, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel: +91 11 4302 5608
Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 099.
Tel: +91 22 6758 8888, Fax: +91 22 6758 8811 / 8833
Website: www.aprava.com | CIN: U40104DL2008PLC374107



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025

Jhajjar Power Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/jhajjar-power-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debit-ether/qrcode/9520111/debit-corp-announcements>).



Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Jhajjar Power Limited

Sd/-
Bhaskar Bhattacharjee

Whole-time Director
(DIN: 06309161)

Date: 12 November 2025
Place: Mumbai, India

Eris

ERIS LIFESCIENCES LIMITED

Regd. Office: Shivarth Ambit, Plot No 14/22, Ramdas Road Off SBR, Near Swast Bungalows, Bodakdev, Ahmedabad, Gujarat-380054. Email: compliance.officer@erislifesciences.com Website: www.eris.co.in
Tel: +91 79 6966 1000, Fax: +91 79 6966 1155, CIN: L24232GJ2007PLC049867

EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Particulars	[₹ in crores except per share data]					
	For Quarter Ended (Unaudited) September 30, 2025	For Quarter Ended (Unaudited) June 30, 2025	For Quarter Ended (Unaudited) September 30, 2024	For Half Year Ended (Unaudited) September 30, 2025	For Half Year Ended (Unaudited) September 30, 2024	For Year Ended (Audited) March 31, 2025
Revenue from Operations	792.41	773.00	741.17	1,565.41	1,460.89	2,893.64
Net Profit for the period before tax and exceptional items	172.67	161.10	129.21	333.77	244.73	468.87
Net Profit for the period before tax and after exceptional items	172.67	161.10	129.21	333.77	244.73	468.87
Net Profit for the period after tax	134.47	125.10	96.41	259.57	185.96	374.67
Total Comprehensive Income for the period after tax	133.90	124.53	96.25	258.43	185.01	371.38
Equity Share Capital (Face Value of ₹1 each)	13.62	13.62	13.61	13.62	13.61	13.62
Other Equity	3,077.54	2,960.97	2,757.87	3,077.54	2,757.87	2,840.74
Net Worth	3,053.48	3,099.10	3,177.34	3,053.48	3,177.34	3,271.76
Paid-up Debt Capital/Outstanding Debt	2,334.37	2,448.61	2,695.24	2,334.37	2,695.24	2,421.66
Outstanding Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
Debt Equity Ratio	0.68	0.74	0.86	0.68	0.86	0.76
Earnings Per Share (of ₹1 each) (not annualised):						
Basic	8.82	8.66	6.73	17.49	12.84	25.85
Diluted	8.81	8.64	6.72	17.46	12.82	25.81
Capital Redemption Reserve	0.17	0.17	0.17	0.17	0.17	0.17
Debit Redemption Reserve	-	-	-	-	-	-
Debt Service Coverage Ratio	2.65	2.60	2.15	2.63	2.18	2.24
Interest Service Coverage Ratio	4.48	4.29	3.17	4.39	3.04	3.11

Notes: 1. Summary of standalone financial results of Eris Lifesciences Limited:

Particulars	[₹ in crores except per share data]					
	For Quarter Ended (Unaudited) September 30, 2025	For Quarter Ended (Unaudited) June 30, 2025	For Quarter Ended (Unaudited) September 30, 2024	For Half Year Ended (Unaudited) September 30, 2025	For Half Year Ended (Unaudited) September 30, 2024	For Year Ended (Audited) March 31, 2025
Revenue from Operations	650.50	578.64	436.56	1,229.14	893.25	1,697.75
Profit before tax	234.67	156.26	46.02	390.93	72.84	120.05
Profit after tax	149.57	99.99	28.10	249.56	45.14	77.39
Total Comprehensive Income (after tax)	149.07	99.49	27.99	248.56	44.31	74.55

2. The above is an extract of the detailed format of quarterly financial results filed with the stock exchange under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the stock exchanges websites (www.nseindia.com and www.bseindia.com) and on the company's website www.eris.co.in.

3. For the other line items referred in Regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to the Stock Exchange(s) (www.nseindia.com) and can be accessed on the company's website www.eris.co.in.

4. The above results were reviewed by the Audit Committee and approved by the Board at their meeting held on November 12, 2025.



Place: Ahmedabad
Date: November 12, 2025

For Eris Lifesciences Limited
Sd/-
Chairman and Managing Director

(Address: 907/23)



LAXMI DENTAL LIMITED

(Formerly known as Laxmi Dental Export Private Limited)

Registered Office: OFFICE NO. 103, AKRUTI ARCADE, J.P. ROAD, OPPOSITE A.H. WADIA HIGH SCHOOL, ANDHERI WEST, MUMBAI, MAHARASHTRA, INDIA, 400058

Tel: +91 22 6143 7991 E-mail: co.se@laxmidentallimited.com Website: www.laxmidentallimited.com

EXTRACTS OF THE UNAUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

(Rs in Millions)

Particulars	Consolidated						Standalone					
	Quarter ended September 30, 2025 (Unaudited)	Quarter ended June 30, 2025 (Unaudited)	Quarter ended September 30, 2024 (Unaudited)	Quarter ended June 30, 2024 (Unaudited)	Quarter ended September 30, 2023 (Unaudited)	Quarter ended June 30, 2023 (Unaudited)	Quarter ended September 30, 2025 (Unaudited)	Quarter ended June 30, 2025 (Unaudited)	Quarter ended September 30, 2024 (Unaudited)	Quarter ended June 30, 2024 (Unaudited)	Quarter ended September 30, 2023 (Unaudited)	Quarter ended June 30, 2023 (Unaudited)
1 Total Income from operations	722.65	655.97	571.19	1,378.62	1,167.80	2,391.08	542.57	501.12	419.83	1,043.70	852.17	1,712.43
2 Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	94.22	95.95	48.77	190.17	144.86	248.02	72.75	89.96	25.39	162.71	85.64	173.27
3 Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	94.22	95.95	48.77	190.17	211.03	318.29	72.75	89.96	25.39	162.71	151.81	243.54
4 Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	85.32	83.30	58.95	168.62	227.39	318.34	65.70	78.59	37.96	144.29	183.84	257.75
5 Total Comprehensive Income (after tax)	87.35	82.46	59.83	169.81	227.17	313.00	64.33	77.22	36.38	141.55	182.26	252.27
6 Equity Share Capital (Face Value Rs 2 each)	109.92	109.92	55.63	109.92	55.63	109.92	109.92	109.92	55.63	109.92	55.63	109.92
7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	1,975.45	-	-	-	-	-	2,117.45
8 Earning Per Share of Rs 2 each (before and after extraordinary items)												
Basic:	1.59	1.53	1.14	3.12	4.39	6.07	1.20	1.43	0.73	2.63	3.55	4.92
Diluted:	1.58	1.52	1.14	3.10	4.39	6.05	1.19	1.42	0.73	2.61	3.55	4.91

Notes:

a. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 11, 2025.
b. The above is an extract of the detailed format of the Consolidated and Standalone Financial Results for the quarter and half year ended September 30, 2025 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the websites of the Company, National Stock Exchange of India Limited and BSE Limited at www.laxmidentallimited.com, www.nseindia.com and www.bseindia.com, respectively.

Place: Mumbai
Date: November 11, 2025



For and on behalf of the Board of Directors
Sd/-
Sanjeev Kamlesh Merchant

CEO & Managing Director
(DIN: 00679893)



PHARMAIDS PHARMACEUTICALS LIMITED

CIN - L5250KA1989PLC173079

Registered Office: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore-560013, INDIA. Tel: 080-49784319
E-mail Id: compliance@pharmalids.com | Website: www.pharmalids.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER, 2025.

The Board of Pharmalids Pharmaceuticals Limited (the Company), at its Meeting held on Tuesday, November 11, 2025, approved the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025.



The said financial results along with Limited Review Reports are available on Stock Exchange website (www.bseindia.com) and on the Company's website (<https://www.pharmalids.com/financialresults.html>). The same can be accessed by scanning the Quick Response Code provided.

By order of the Board of Directors
For Pharmalids Pharmaceuticals Limited

Sd/-
Venu Madhava Kaparthi
Whole-Time Director
(DIN:00021699)

Date: 11-11-2025, Place: Bengaluru

Note: The above information is in accordance with Regulations 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

KOHIMA-MARIANI TRANSMISSION LIMITED

(An Aprava Energy Company)

Registered Office: Unit No. T-15 A, Salcon Ras Vias, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel: +91 11 4302 5608
Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 999.
Tel: +91 22 6756 8888, Fax: +91 22 6756 8811 / 8833
Website: www.aprava.com | CIN: U40102DL2016PLC403233



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025

Kohima-Mariani Transmission Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/kohima-mariani-transmission-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debt-issuer/corporate/9759311-debt-corp-announcements>).



Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Kohima-Mariani Transmission Limited

Sd/-
Deepa Sebastian
Director
(DIN: 09443732)

Date: 12 November 2025
Place: Mumbai, India



MULTIBASE INDIA LIMITED

Regd. Off & Factory Site: 74/5-B, Danner Industrial Estate, Kadiyala Village, Near Danner - 206 210 (Union Territory)
• Phone: (0260) 6614400 • Fax: (0260) 2221578 • Website: www.multibaseindia.com
• E-mail: compliance.officer@multibaseindia.com • CIN: L01122DD1991PLC002959

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Sr. No.	Particular	Quarter Ended						Half Year Ended		Year Ended
		Quarter ended September 30, 2025	Quarter ended June 30, 2025	Quarter ended September 30, 2024	Quarter ended June 30, 2024	Quarter ended September 30, 2023	Quarter ended June 30, 2023	Half year ended September 30, 2025	Half year ended June 30, 2025	Year ended March 31, 2025
1	Total Income from Operations	1,930.16	1,762.47	2,043.63	3,692.63	4,159.89	7,680.65			
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	386.39	307.83	575.70	694.22	1101.60	1969.39			
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	386.39	307.83	575.70	694.22	1101.60	1969.39			
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	286.29	229.65	428.80	515.94	821.07	1465.49			
5	Total Comprehensive Income (Comprising Profit / (Loss) after tax and Other Comprehensive Income after tax)	286.29	229.65	428.80	515.94	821.07	1465.49			
6	Equity Share Capital (Face value of share: ₹10/-)	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00	1,262.00			
7	Other Equity	7,104.92	0.00	12,637.19	7,104.92	12,637.19	6,588.96			
8	Earnings per equity share in ₹									
(i) Basic:		2.37	1.82	3.40	4.08	6.51	11.81			
(ii) Diluted:		2.37	1.82	3.40	4.08	6.51	11.81			

Notes: The above is an extract of the detailed format of unaudited financial results for the quarter and nine months ended September 30, 2025 filed with BSE Ltd. under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the said quarter is available on the website of BSE Ltd. at www.bseindia.com and company's website at www.multibaseindia.com. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025.

REDEMPTION OF TRANSFER DEEDS

Please note that a special window has been opened for the re-issuance of transfer deeds. This window is available for transfer deeds lodged before the deadline of April 01, 2019, which were rejected, returned, or unutilized due to deficiencies in the documents, processes, or other reasons. This special window will remain open for six months, from July 07, 2025, until January 06, 2026.

SAKSHAM NIVESHAK

Multibase India Limited is proud to support the IEPPA Saksham Niveshak 100-Day Campaign an initiative designed to help investors reclaim forgotten shares and undivided dividends. If you or someone you know has lost track of physical share certificates or dividends, now is the time to act.



For Multibase India Limited
Sd/-
Pankaj Kumar Halani
(Managing Director)
(DIN 10643892)

Place: Mumbai
Date: November 12, 2025

JHAJJAR POWER LIMITED

(An Aprava Energy Company)

Registered Office: Unit No. T-15 B, Salcon Ras Vias, 3rd Floor, Plot No. D-1, Saket District Centre, Saket, New Delhi - 110 017. Tel: +91 11 4302 5608
Corporate Office: 7th Floor, Fulcrum, Sahar Road, Andheri (East), Mumbai - 400 999.
Tel: +91 22 6756 8888, Fax: +91 22 6756 8811 / 8833
Website: www.aprava.com | CIN: U40104DL2008PLC374107



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF-YEAR ENDED 30 SEPTEMBER 2025

Jhajjar Power Limited (the "Company") hereby informs that the Audit Committee and the Board of Directors of the Company at their respective meetings held on Wednesday, 12 November 2025, inter alia, have considered and approved the Unaudited Financial Results of the Company for the quarter and half-year ended 30 September 2025 ("Results") along with the Limited Review Report thereon, issued by the Statutory Auditors of the Company.

In accordance with Regulation 52 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), the aforesaid Results are now being made available through a Quick Response Code ("QR Code") given below and the same are also published on the websites of the Company (<https://www.aprava.com/investor-and-compliance/jhajjar-power-limited>) and the Stock Exchange i.e., BSE Limited (<https://www.bseindia.com/stock-share-price/debt-issuer/corporate/9520111-debt-corp-announcements>).



Scan the QR Code to view the Results on the website of the Company



Scan the QR Code to view the Results on the website of BSE Limited

For and on behalf of Board of Directors of Jhajjar Power Limited

Sd/-
Bhaskar Bhattacharjee
Whole-time Director
(DIN: 06309161)

Date: 12 November 2025
Place: Mumbai, India



ERIS LIFESCIENCES LIMITED

Regd. Office: Shivarth Ambit, Plot No 142/2, Ramdas Road Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat-380054. Email: compliance.officer@erislifesciences.com Website: www.eris.co.in
Tel: +91 79 6966 1000, Fax: +91 79 6966 1155, CIN: L24232GJ2007PLC049867

EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

Particulars	[₹ in crores except per share data]					
	For Quarter Ended (Unaudited) September 30, 2025	For Quarter Ended (Unaudited) June 30, 2025	For Quarter Ended (Unaudited) September 30, 2024	For Half Year Ended (Unaudited) September 30, 2025	For Half Year Ended (Unaudited) September 30, 2024	For Year Ended (Audited) March 31, 2025
Revenue from Operations	792.41	773.00	741.17	1,565.41	1,460.89	2,893.64
Net Profit for the period before tax and exceptional items	172.67	161.10	129.21	333.77	244.73	468.87
Net Profit for the period before tax	172.67	161.10	129.21	333.77	244.73	468.87
Net Profit for the period after tax	134.47	125.10	96.41	258.57	185.96	374.67
Total Comprehensive Income for the period after tax	133.90	124.53	96.25	258.43	185.01	371.38
Equity Share Capital (Face Value of ₹1 each)	13.62	13.62	13.61	13.62	13.61	13.62
Other Equity	3,077.54	2,960.97	2,757.87	3,077.54	2,757.87	2,840.74
Net Worth	3,053.48	3,399.10	3,177.34	3,053.48	3,177.34	3,271.76
Paid-up Debt Capital/Outstanding Debt	2,334.37	2,448.61	2,695.24	2,334.37	2,695.24	2,421.86
Outstanding Redeemable Preference Shares	NA	NA	NA	NA	NA	NA
Debt Equity Ratio	0.68	0.74	0.86	0.68	0.86	0.76
Earnings Per Share (of ₹1 each) (not annualised):						
Basic:	8.82	8.66	6.73	17.49	12.84	25.85
Diluted:	8.81	8.64	6.72	17.46	12.82	25.81
Capital Redemption Reserve	0.17	0.17	0.17	0.17	0.17	0.17
Debt Service Coverage Ratio	2.65	2.60	2.15	2.63	2.18	2.24
Interest Service Coverage Ratio	4.48	4.29	3.17	4.39	3.04	3.11

Notes: 1. Summary of standalone financial results of Eris Lifesciences Limited:

Particulars	[₹ in crores except per share data]					
	For Quarter Ended (Unaudited) September 30, 2025	For Quarter Ended (Unaudited) June 30, 2025	For Quarter Ended (Unaudited) September 30, 2024	For Half Year Ended (Unaudited) September 30, 2025	For Half Year Ended (Unaudited) September 30, 2024	For Year Ended (Audited) March 31, 2025
Revenue from Operations	650.50	578.64	436.56	1,229.14	893.25	1,697.75
Profit before tax	234.67	156.26	46.02	390.93	72.84	120.05
Profit after tax	149.57	99.99	28.10	249.56	45.14	77.39
Total Comprehensive Income (after tax)	149.07	99.49	27.99	248.56	44.31	74.55

2. The above is an extract of the detailed format of quarterly financial results, filed with the stock exchange under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results is available on the stock exchanges websites (www.nseindia.com and www.bseindia.com) and on the company's website www.eris.co.in.

3. For the other line items referred in Regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to the Stock Exchange(s) (www.nseindia.com and www.bseindia.com) and can be accessed on the company's website www.eris.co.in.

4. The above results were reviewed by the Audit Committee and approved by the Board at their meeting held on November 12, 2025.



Place: Ahmedabad
Date: November 12, 2025

For Eris Lifesciences Limited
Sd/-
Chairman and Managing Director

(Address: 807/2)



LAXMI DENTAL LIMITED

(Formerly known as Laxmi Dental Export Private Limited)

Registered Office: OFFICE NO. 103, AKRUTI ARCADE, J.P. ROAD, OPPOSITE A.H. WADIA HIGH SCHOOL, ANDHERI WEST, MUMBAI, MAHARASHTRA, INDIA, 400058
Tel: +91 22 6143 7991 E-mail: co.secl@laxmidentallimited.com Website: www.laxmidentallimited.com
(CIN: L51507MH2004PLC147394)

EXTRACTS OF THE UNAUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

(Rs in Millions)

Particulars	Consolidated						Standalone					
	Quarter ended September 30, 2025 (Unaudited)	Quarter ended June 30, 2025 (Unaudited)	Quarter ended September 30, 2024 (Unaudited)	Quarter ended September 30, 2025 (Unaudited)	Quarter ended June 30, 2025 (Unaudited)	Quarter ended September 30, 2024 (Unaudited)	Quarter ended September 30, 2025 (Unaudited)	Quarter ended June 30, 2025 (Unaudited)	Quarter ended September 30, 2024 (Unaudited)	Quarter ended September 30, 2025 (Unaudited)	Quarter ended June 30, 2025 (Unaudited)	Quarter ended September 30, 2024 (Unaudited)
1 Total Income from operations	722.65	655.97	571.19	1,378.62	1,167.80	2,391.08	542.57	501.12	419.83	1,043.70	852.17	1,712.43
2 Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	94.22	95.95	48.77	190.17	144.86	248.02	72.75	89.96	25.39	162.71	85.64	173.27
3 Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	94.22	95.95	48.77	190.17	144.86	248.02	72.75	89.96	25.39	162.71	85.64	173.27
4 Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	85.32	83.30	58.95	168.62	227.39	318.34	65.70	78.59	37.96	144.29	183.84	257.75
5 Total Comprehensive Income (after tax)	87.35	82.46	59.83	169.81	227.17	313.00	64.33	77.22	36.38	141.55	182.26	252.27
6 Equity Share Capital (Face Value Rs 2 each)	109.92	109.92	55.63	109.92	55.63	109.92	109.92	109.92	55.63	109.92	55.63	109.92
7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	1,975.45	-	-	-	-	-	2,117.45
8 Earning Per Share of Rs 2 each (before and after extraordinary items)												
Basic:	1.59	1.53	1.14	3.12	4.39	6.07	1.20	1.43	0.73	2.63	3.55	4.92
Diluted:	1.58	1.52	1.14	3.10	4.39	6.05	1.19	1.42	0.73	2.61	3.55	4.91

Notes:

a. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 11, 2025.
b. The above is an extract of the Audited format of the Consolidated and Standalone Financial Results for the quarter and half year ended September 30, 2025 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the websites of the Company, National Stock Exchange of India Limited and BSE Limited at www.laxmidentallimited.com, www.nseindia.com and www.bseindia.com, respectively.

Place: Mumbai
Date: November 11, 2025



For and on behalf of the Board of Directors
Sd/-
Sanjeev Kamlesh Merchant
CEO & Managing Director
(DIN: 00679893)

ભગવાન બિરસા મુંડાની ૧૫૦મી જન્મજયંતિ, જનજાતિય ગૌરવ વર્ષ ઉજવણી માંડવી તાલુકા મથકે રાષ્ટ્રનિર્માણમાં આદિજાતિ સમાજના ગૌરવપૂર્ણ યોગદાનને જન-જન સુધી પહોંચાડવાના ઉદ્દેશ્ય સાથે આયોજિત જનજાતિય ગૌરવ રથ યાત્રાનું આદિજાતિ વિકાસ મંત્રી નરેશભાઈ પટેલ તથા ધારાસભ્ય કુંવરજીભાઈ હળપતિએ ભવ્ય સ્વાગત કર્યું

સુરતઃ બુધવાર:- ભગવાન બિરસા મુંડાની ૧૫૦મી જન્મજયંતિની ઉજવણી થઈ રહી છે, ત્યારે રાષ્ટ્રનિર્માણમાં આદિજાતિ સમાજના ગૌરવપૂર્ણ યોગદાનને જન-જન સુધી પહોંચાડવાના ઉદ્દેશ્ય સાથે ‘જનજાતીય ગૌરવ વર્ષ મહોત્સવ’ની ઉજવણીના ભાગરૂપે આદિજાતિ વિકાસ વિભાગ દ્વારા આયોજિત ‘જનજાતીય ગૌરવ રથયાત્રા માંડવી તાલુકા મથકે આવી પહોંચી હતી, જ્યાં આદિજાતિ વિકાસ મંત્રી નરેશભાઈ પટેલ અને પૂર્વ મંત્રી અને ધારાસભ્ય કુંવરજીભાઈ હળપતિએ ભવ્ય સ્વાગત કર્યું હતું.

સુપ્રીમે ચિંતા વ્યક્ત કરી દિલ્હીમાં હિન્દી નહીં બોલવા મુદ્દે કેરળના વિદ્યાર્થીઓને માર્યા ૨૦૧૫ના વર્ષમાં ઉત્તરપૂર્વના લોકો પર સંખ્યાબંધ હુમલાઓની ઘટનાઓમાં અરુણાચલ પ્રદેશના એક વિદ્યાર્થીનું મોત થયું હતું

નવી દિલ્હી, એસ.એસ.એસ., તા. ૧૨ઃ ભાષા અને વંશીય તફાવતનું બહાનું આગળ ધરી દેશમાં વિઘટકારી માનસિકતાનો પ્રભાવ વધી રહ્યો હોવા બાબતે સુપ્રીમ કોર્ટે ચિંતા વ્યક્ત કરી છે. દેશની રાજધાની દિલ્હીમાં લાલ કિલ્લા નજીક કેરળના બે વિદ્યાર્થીઓને હિન્દી બોલવા માટે પોલીસ અને સ્થાનિકોએ માર માર્યો હતો અને ધમકાવ્યા હતા. તેમણે કેરળનો પરંપરાગત પોશાક પહેર્યો હોવાથી દિલ્હીમાં તેમની મજાક પણ ઉડાવવામાં આવી હતી. દિલ્હી યુનિવર્સિટીની ઝાકિર હુસૈન દિલ્હી કોલેજના ફર્સ્ટ યરના બે વિદ્યાર્થીએ લુંગી પ હેરેલી હતી અને તેઓ હિન્દીમાં વાત કરતા ન હતા. જેના કારણે તેમને માર મારીને અપમાન કરવામાં આવ્યું હતું. ૨૦૧૫ના વર્ષમાં ઉત્તરપૂર્વના લોકો પર સંખ્યાબંધ હુમલાઓની ઘટનાઓમાં અરુણાચલ પ્રદેશના એક વિદ્યાર્થીનું મોત થયું હતું. આ કેસની સુનાવણી દરમિયાન જસ્ટિસ સંજય કુમાર અને જસ્ટિસ આલોક આરાધેની બેન્ચે નોંધ્યુ હતું કે, સાંસ્કૃતિક અને વંશીય તફાવતના કારણે દેશમાં

કમોસમી વરસાદ બાદ પંચાયત, માર્ગ અને મકાન વિભાગ દ્વારા ડાંગ જિલ્લામાં માર્ગ અને પુલના કામો પુરજોશમાં શરૂ કરાયાં

આહવા: તા: ૧૨ઃ તાજેતરમાં વરસેલાં કમોસમી વરસાદ બાદ ડાંગ જિલ્લા પંચાયત માર્ગ અને મકાન વિભાગ દ્વારા માર્ગ તથા પુલના વિકાસના વિવિધ કાર્યો પુરજોશમાં શરૂ કરવામાં આવ્યા છે. જિલ્લાના પંચાયત માર્ગ અને મકાન વિભાગ દ્વારા ગ્રામ્ય વિસ્તારોમાં બિટુમિન રોડના કામો, પુલના માળખાકીય તથા સમાપ્તી કાર્યો ઝડપથી હાથ ધરવામાં આવ્યા છે, જેથી વરસાદ બાદ માર્ગવ્યવસ્થા વધુ સુગમ અને સુરક્ષિત બને. આ સાથે જ વિભાગના ઈજનેરી સ્ટાફ દ્વારા સ્થળ પર સતત દેખરેખ સાથે ગુણવત્તાયુક્ત કામો કરવામાં આવી રહ્યા છે. તાજેતરમાં જ ડાંગ જિલ્લા પંચાયત માર્ગ અને મકાન વિભાગ આહવા દ્વારા પુલના સુપરસ્ટ્રક્ચરનું સમાપ્તી અને પરાંપટે પેઈન્ટિંગ કાર્ય, મશીન વડે બિટુમિન પાથરી પેવર અને રોલરથી સમતલ માર્ગ નિર્માણ, ઉચ્ચ અધિકારીઓના માર્ગદર્શન હેઠળ તમામ કાર્યો સમયમર્યાદામાં અને ગુણવત્તા ધોરણો મુજબ પૂર્ણ કરવા માટે ખાસ ધ્યાન જેવાં વિભાગના મહત્વના કાર્યો પૂર્ણ કરવામાં આવ્યા છે.

યોજાઈ રહી છે. આ તકે મંત્રીએ સૌ રાજ્ય સરકારે ‘જનજાતિય ગૌરવ રથ યાત્રા’ના માધ્યમથી નવી પહેલ કરી છે, ત્યારે આગામી તા. ૧૫મી નવેમ્બરના રોજ ડેડિયાપાડા ખાતે વડાપ્રધાનની પ્રેરક ઉપસ્થિતિમાં થનાર ઉજવણીમાં સૌને સહભાગી બનવા અનુરોધ કર્યો હતો. આ પ્રસંગે માંડવી પ્રાયોજના વહીવટદાર સુનીલકુમારે સ્વાગત પ્રવચન કરીને જનનાયક બિરસા મુંડાએ દેશ માટે આપેલા બલિદાન વિગતો આપીને સૌને આવકાર્યા હતા. આ પ્રસંગે શાળાના વિદ્યાર્થીઓએ ઉત્સાહ અને ઉમંગ સાથે

એસ. એસ. એસ., તા. ૧૨ઃ અમદાવાદના જમાલપુર વિસ્તારમાં ૧૬ વર્ષ પછી મ્યુનિસિપલ કોર્પોરેશને મેગા ડિમોલિશન હાથ ધર્યું હતું. ઊંટવાળી ચાલી પાસે મ્યુનિસિપલ કોર્પોરેશનની જગ્યામા કુખ્યાત બિલાલ શેખના બાંધકામ સહિત કુલ ૩૦ દુકાનો ચુસ્ત પોલીસ બંદોબસ્ત સાથે એરેસ્ટ વિભાગે તોડી પાડી હતી. જમાલપુર ત્રિકમજીના મંદિરની જગ્યા પ ચાલી પાડનાર બિલાલ ગેરકાયદે દબાજ કરી ભાડા વસૂલતો હતો. સૂત્રો પાસેથી મળતી માહિતી મુજબ, કોર્પોરેશન તેની કામગીરી હજુ એક-બે દિવસ ચલાવશે તથા ૧૮ હજાર વાર જગ્યા ખુલ્લી કરાશે. જમાલપુરમાં લાટી બજાર તરીકે જાણીતી જગ્યા મ્યુનિસિપલ કોર્પોરેશન દ્વારા ભાડાપટ્ટેથી આપ્યા હતા.

ડાંગ જિલ્લામાં ધંધા રોજગાર ધરાવતા એકમોને અસંગઠિત શ્રમિકો/કામદારોની નોંધણી કરવાની સૂચના

આહવા: તા: ૧૨ઃ રાજ્યના છેવાડે અને અંતરણ્ય રાજ્ય સરહદને અડીને આવેલા ડાંગ જિલ્લામા કાર્યરત અલગ અલગ એકમો, ખાનગી એકમો, કોન્સ્ટ્રક્ટરો, ઈંટના ભઠ્ઠા તથા તમામ પ્રકારના ધંધા/રોજગાર ધરાવતા એકમો દ્વારા અસંગઠિત શ્રમિકો/કામદારોને આપવામા આવતા રોજગાર સાથે જ આવા કામદારો/શ્રમિકોની સાચી ઓળખ પ્રસ્થાપિત થાય તે માટે તેમની નોંધણી કરજિયાતપણે થાય તે સુનિશ્ચિત કરવાની સૂચના જારી કરાઈ છે. ડાંગના અધિક જિલ્લા મેજિસ્ટ્રેટ વી.કે. જોશી દ્વારા જારી કરાયેલા એક જાહેરનામા અનુસાર આવા ધંધા/રોજગાર ધરાવતા એકમોને શ્રમિક/કામદારોને રોજગારીએ/કામે રાખતા પહેલા તેમનો પૂર્વ ઈતિહાસ જાણી, તેમની ઓળખ પ્રસ્થાપિત કરવાની રહેશે. સાંપ્રત સ્થિતિને લક્ષમા લઈ હાથ ધરવાની થતી આ પ્રક્રિયાના ભાગરૂપે આવા એકમોએ શ્રમિક/કામદારોની સંપૂર્ણ વિગતોની નોંધણી નજીકના પોલીસ સ્ટેશનમા કરજિયાતપણે કરવાની રહેશે. જો તેમ કરવામા કસૂર થાય કે આ જાહેરનામાનો ભંગ કરવામા આવશે તો આવા એકમો/ધંધો રોજગાર આપતી સંસ્થાઓ સામે કાયદેસરની કાર્યવાહી હાથ ધરાશે. આ જાહેરનામું તા. ૦૮ જાન્યુઆરી ૨૦૨૬ સુધી અમલમાં રહેશે તેમજ આ જાહેરનામોનો ભંગ કરનાર શિક્ષાને પાત્ર ઈરશે, તેમ આ જાહેરનામામા જણાવાયું છે.

યોગદાનને ઉજાગર કરવા માટે કેન્દ્ર અને રાજ્ય સરકારે ‘જનજાતિય ગૌરવ રથ યાત્રા’ના માધ્યમથી નવી પહેલ કરી છે, ત્યારે આગામી તા. ૧૫મી નવેમ્બરના રોજ ડેડિયાપાડા ખાતે વડાપ્રધાનની પ્રેરક ઉપસ્થિતિમાં થનાર ઉજવણીમાં સૌને સહભાગી બનવા અનુરોધ કર્યો હતો. આ પ્રસંગે માંડવી પ્રાયોજના વહીવટદાર સુનીલકુમારે સ્વાગત પ્રવચન કરીને જનનાયક બિરસા મુંડાએ દેશ માટે આપેલા બલિદાન વિગતો આપીને સૌને આવકાર્યા હતા. આ પ્રસંગે શાળાના વિદ્યાર્થીઓએ ઉત્સાહ અને ઉમંગ સાથે

૧૬ વર્ષ બાદ મેગા ડિમોલિશન

જમાલપુરમાં પોલીસ બંદોબસ્ત વચ્ચે તોડી પડાઈ ૩૦ દુકાન

જમાલપુરમાં મ્યુનિસિપલ કોર્પોરેશને દ્વારા ભાડાપટ્ટેથી આપી હતી લાટી બજાર તરીકે જાણીતી જગ્યા

આપવામા આવી હતી. ભાડા પટ્ટેથી આપવામા આવેલી જગ્યાનો કરાર વર્ષ-૨૦૦૮માં પૂરો થઈ ગયો હતો. આમ છતાં જે તે સમયના મધ્ય ઝોનના ડેપ્યુટી એસ્ટેટ ઓફિસરથી લઈ અન્ય કોઈ અધિકારીઓ દ્વારા જગ્યાનું ફરીથી પંચેશન મેળવવા કોઈ નક્કર કાર્યવાહી કરવામા આવી નહોતી. વર્ષ-૨૦૦૮થી બિલાલ શેખ દ્વારા આ જગ્યા ઉપર ગેરકાયદે દબાજ કરવાની સાથે ગેરકાયદે ઊભી કરી દેવામા આવેલી દુકાનોના ભાડા વસૂલવામા આવતા હતા. બિલાલ ઉપરાંત હનીફ દાદી ઉર્ફે હનીફ શેખ વિરૂદ્ધ અનેક ગુના નોંધાયેલા છે. ગાયકવાડ હવેલી પોલીસ સ્ટેશનમા પણ બિલાલ શેખ વિરૂદ્ધ ગુનો નોંધાયેલો છે. ૧૬ વર્ષથી કોર્પોરેશનની જગ્યામાં ગેરકાયદે બાંધકામ કરી જગ્યા ૫

આદિવાસી સાંસ્કૃતિક કૃતિઓ રજૂ કરી હતી. આ પ્રસંગે મંત્રી તથા અન્ય મહાનુભાવોના હસ્તે કિસાન પરિવહન યોજના, પીએમ જનમન તથા હળપતિ આવાસ યોજનાના લાભાર્થીઓને ચાવીનું વિતરણ કરાયું હતું. આ પ્રસંગે વિધાનસભા નાયબ દંડક વિજયભાઈ પટેલ, જિ. સંગઠન પ્રમુખ ભરતભાઈ રાઠોડ, અગ્રણી સર્વે અર્જુનભાઈ ચૌધરી, માંડવીના પ્રાંત અધિકારી, મામલતદાર, તા.વિકાસ અધિકારી, અગ્રણી જીગર નાયક, નિમેષભાઈ તથા મોટી સંખ્યામાં નગરજનો ઉપસ્થિત રહ્યા હતા.

આ પાછળ મ્યુનિસિપલ કોર્પોરેશનના અધિકારીઓ સાથે ગોઠવણ કરી દુકાનો ઊભી કરી ગેરકાયદે ભાડા પણ વસૂલાતા હતા. તેમ છતાં કોર્પોરેશનના અત્યાર સુધીના હોદ્દાદારોએ પણ આ સમગ્ર મામલે કામગીરી કરવાનું તો દૂર પણ કંઈ બોલવા અંગે પણ ચૂપકીરી સેવી લીધી હતી. જમાલપુરમાં કોર્પોરેશનની જગ્યામાં ગેરકાયદે દબાજ કરનારા બિલાલ શેખનો ભાઈ સોએબ શેખ શહેર ભાજપ સંગઠનમાં મહામંત્રી છે. સૂત્રો પાસેથી મળતી માહિતી મુજબ, હનીફ દાદીના બે પુત્ર પૈકી સોએબ ભાજપ શહેર સંગઠનમાં સક્રિય છે અને ભાજપના અનેક નેતાઓ સાથે તેના ધનિક સંબંધ હોવાના કારણે પણ જમાલપુરમાં કોર્પોરેશનની જગ્યા અત્યાર સુધી ખાલી કરાવાતી નહોતી.

ડાંગ જિલ્લામાં મોટા અવાજવાળા ફટાકડા ફોડવા અને ડ્રોન ઉડાવવા ઉપર પ્રતિબંધ ફરમાવાયો

આહવા: તા: ૧૨ઃ ડાંગ જિલ્લામાં હાલની પરિસ્થિતિને ધ્યાને લઈ જિલ્લામાં કાયદો અને વ્યવસ્થા જળવાઈ રહે તેમજ સુલેહ શાંતિનો ભંગ ન થાય તે માટે સમગ્ર ડાંગ જિલ્લામાં મોટા અવાજવાળા ફટાકડા ફોડવા તથા ડ્રોન ઉડાડવા ઉપર પ્રતિબંધ ફરમાવવા માટે ડાંગ- આહવાના અધિક જિલ્લા મેજિસ્ટ્રેટ વિ.કે. જોષી (જી.એ.એસ.)એ ભારતીય નાગરિક સુરક્ષા સંહિતા (BNSS)–૨૦૨૩ ની કલમ-૧૬૩ થી મળેલી સત્તાની રૂએ જાહેરનામુ બહાર પાડ્યુ છે. આ હુકમ તા. ૧૧/૧૧/૨૦૨૫ ના ક.૦૦/૦૦ થી તા. ૦૮/૦૧/૨૦૨૬ ક. ૨૪.૦૦ (બંને દિવસો સહિત) સુધી અમલમાં રહેશે. આ હુકમનો ભંગ કરનાર વ્યક્તિ ભારતીય ન્યાય સંહિતા (BNS)–૨૦૨૩ ની કલમ-૨૨૩ મુજબ શિક્ષાને પાત્ર ઈરશે. આ જાહેરનામાનો ભંગ કરનાર ઈસમો વિરુદ્ધ ફરિયાદ દાખલ કરવા માટે ડાંગ જિલ્લામાં ફરજ બજાવતા નાયબ પોલીસ અધિક્ષક થી હેડ કોન્સ્ટેબલ સુધીનો હોદ્દો ધરાવનાર પોલીસ અધિકારીઓને અધિકૃત કરવામાં આવ્યા છે. ઉપરોક્ત મુજબનું કૃત્ય કરનારા ઈસમો સામે ઉપર મુજબનો કોઈ પણ સામાન પોલીસ તપાસ અર્થે કબજે લઈ શકશે.

ગુજરાત રાજ્ય યોગ બોર્ડ દ્વારા ડાંગ જિલ્લામાં મેદસ્વિતા મુક્ત અભિયાન અંતર્ગત આહવા ખાતે શરૂ કરાયો કેમ્પ

આહવા: તા: ૧૨ઃ સમગ્ર ગુજરાતમાં મેદસ્વિતા એક સમસ્યા બની રહી છે ત્યારે ગુજરાત રાજ્ય યોગ બોર્ડ દ્વારા દરેક જિલ્લામાં કુલ ૧૦૦ જેટલા સ્થળોએ એક સાથે ૧૦ નવેમ્બર થી ૧૦ ડિસેમ્બર સુધી મેદસ્વિતા મુક્ત અભિયાન ચલાવનાર છે. જેમાં ડાંગ જિલ્લા ખાતે ગુજરાત રાજ્ય યોગ બોર્ડ ચેરમેન શિશુપાલજીના માર્ગદર્શન હેઠળ ઝોન કો ઓર્ડિનેટર પ્રીતિબેન પાંડના અધ્યક્ષપણામાં શબરી ભવન આહવા, પટેલપાડા ખાતે મેદસ્વિતા કેમ્પનો પ્રારંભ કરવામાં આવ્યો છે. આ કેમ્પમાં કુલ ૪૦ લાભાર્થીઓ લાભ લઈ શકે છે. આ કેમ્પમાં યોગ ક્રોચ તરીકે ભોયે સરિતા ભેન, કાપડિયા નેહાબેન, અને ગાંડગું ઉમાકાન્તભાઈ

મેદસ્વિતા નિવારણ માટે ના યોગ બોર્ડની ગાઈડ લાઈન અનુસાર યોગ, આસન, પ્રાણાયામ અને ધ્યાન તેમજ ઝુંબા કરાવે છે. મેદસ્વી લોકો માટે આહારનું માર્ગદર્શન આપવામાં આવે છે. કેમ્પ નો સમય સવારે ૬:૦૦ થી ૩:૩૦ નો છે. ૩:૩૦ એ મેદસ્વિતા નિવારણ ઉકાળો આપવામાં આવે છે. કેમ્પના લાભાર્થી નિયમિત રહે તે માટે કેમ્પ માત્ર ૩૦૦ રૂપિયા રજિસ્ટ્રેશન પેટે આપવાના હોય છે. સમગ્ર કેમ્પ જિલ્લા યોગ કો ઓર્ડિનેટર ક્રિયંકાબેન ભોયેની દેખરેખ હેઠળ થઈ રહ્યો છે. મેદસ્વિતા કેમ્પનો લાભ ડાંગ જિલ્લાના વધુમાં વધુ લોકોને પ્રાપ્ત થાય તે હેતુ થી ૯૮૭૦૦૯૮૦૦૬ પર કોલ કરી રજિસ્ટ્રેશન કરવા, આયોજકો દ્વારા અનુરોધ કર્યો.

સારાંશ

સુરત જિલ્લામાં કમોસમી વરસાદ બાદ માર્ગ અને મકાન વિભાગ ૨ દ્વારા વિવિધ રસ્તાઓ પર પેચ વર્કની કામગીરી કરાઈ રસ્તાઓ પર પેચ વર્કની કામગીરી કરાઈ સુરતઃ બુધવાર:- સુરત જિલ્લામાં પંરેલા કમોસમી વરસાદ બાદ માર્ગ અને મકાન વિભાગ ૨ દ્વારા વિવિધ રસ્તાઓ પર પેચ વર્કની કામગીરી કરવામાં આવી હતી. જેમાં તરસાડા-કડોદ-બારડોલી-સરભોણ-નવસારી રોડ કિ.મી. ૫૩/૦૦થી ૫૪/૦૦, સુરત-ઓલાપાડ-સાહોલ રોડ તેમજ નાના વરાછા સેવણી-વિહાણ રોડ કિ.મી. ચેનેજ ૧૭/૪૦ થી ૨૧/૮૫ રોડ પર પેચ વર્ક કરાયું હતું.

સુરતના ઉમરાનું મહેસુલ અધિનિયમ હેઠળ પ્રમોલગેશન પુણ: જાહેર જનતા માટે ખુલ્લું મુકાયું સુરતઃ બુધવાર:- સુરત જિલ્લાના સુરત સિટી તાલુકાના ઉમરા વિસ્તારને સિટી સર્વેમાં દાખલ કરવા જમીન મહેસુલ અધિનિયમ મુજબ મંજૂરી મળી છે. જેથી સિટી સર્વે સુપ્રિન્ટેન્ડન્ટ નં. ૨ની કચેરીના શીટ નં. ૫૮, ચાલત નં. ૦૮ થી ૨૦નું રેકૉર્ડ તૈયાર કરીને તા. ૧૬/૧૧/૨૦૨૫ના રોજ પ્રમાણિત કરવામાં આવનાર છે. આ તૈયાર થયેલા રેકૉર્ડ, પ્રોપર્ટી કાર્ડ, નકશાને સિટી સર્વે સુપ્રિ